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ABSTRACT

Plasma kallikrein plays an important role in the pathogenesis of inflammation and
thrombosis. Kallikrein cleaves high molecular weight kininogen (HK) to liberate the potent proinflammatory peptide bradykinin (BK). BK upon activation of its constitutive B2 receptors on
endothelial cells leads to an increase in intracellular Ca2+ level and subsequent production of
nitric oxide (NO) and prostacyclin (PGI2), ultimately leading to vasodilation, hypotension,
increased vascular permeability and vascular leakage. Further, kallikrein activates the
complement system and stimulates neutrophil chemotaxis, aggregation and elastase release.
Furthermore, kallikrein mediates the conversion of factor XII (FXII) to activated factor XII
(FXIIa) thereby potentiating the intrinsic pathway of coagulation. Thus, plasma kallikrein
represents an important target for the development of novel anti-inflammatory and antithrombotic agents. The primary objective of this study was to develop and characterize a novel
small molecule inhibitor of plasma kallikrein and to evaluate its potential usefulness in the
treatment of kallikrein-mediated inflammatory and thrombotic disorders. Using in vitro
biochemical assays, PF-04886847 was identified as a potent and selective inhibitor of plasma
kallikrein. PF-04886847 inhibited kallikrein-mediated BK production and subsequent BKdependent B2 receptor signaling pathway in cultured endothelial cells. PF-04886847 abolished
BK-induced increase in endothelial monolayer permeability as well as relaxation of
lipopolysaccharide (LPS)-treated isolated rat aortic rings. In a rat model of LPS-induced sepsis
and acute lung injury, PF-04886847 attenuated LPS-mediated increase in granulocyte count in
ii

the systemic circulation and total leukocyte count in the bronchoalveolar lavage fluid. Lastly, in
a balloon-induced femoral artery injury model of thrombosis in hypercholesterolemic rabbits,
PF-04886847 reduced thrombus mass and prolonged both prothrombin time (PT) and activated
partial thromboplastin time (aPTT). Overall, our results indicate that PF-04886847 is a novel,
potent small molecule inhibitor of plasma kallikrein that would be useful for the treatment of
kallikrein-mediated inflammatory and/or thrombotic disorders.
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I. INTRODUCTION

A. Plasma Kallikrein
Plasma kallikrein is a serine protease, which is synthesized predominantly in the liver as
a proenzyme prekallikrein (PK). PK, also known as Fletcher factor, is encoded by a single gene
localized to the q34-q35 region on the long arm of chromosome 4 (Beaubien et al., 1991). The
human PK gene encodes a signal peptide of 19 amino acids and a mature PK with 619 amino
acids (Chung et al., 1986). Mature PK is a single chain γ-globulin zymogen with a molecular
weight of 85-88 kDa and an approximate plasma concentration of 42 µg/mL (~490 nM) (Fisher
et al., 1982). PK has four tandem repeats in the N-terminal region due to the linking of the first
and sixth, second and fifth, and third and fourth half-cysteine residues present in each repeat,
resulting in four groups of 90 or 91 amino acids that are arranged in ‘apple’ domains (McMullen
et al., 1991). At least 75% of PK circulates in the plasma as a complex with the α-globulin, high
molecular weight kininogen (HK) (Mandle et al., 1976). The HK binding sites on PK are located
on the apple domains A1 (Phe56-Gly86) and A4 (Lys266-Gly295) (Figure 1) (Hock et al., 1990; Lin
et al., 1996; Herwald et al., 1996).
PK can be activated to kallikrein by various stimuli including activated factor XII
(αFXIIa) on negatively charged surfaces, factor XII fragment (βFXIIa) in fluid phase and
prolylcarboxypeptidase (PRCP) on endothelial cells (Mandle, Jr. and Kaplan, 1977; ShariatMadar et al., 2002; Wuepper and Cochrane, 1972). Activation of PK to kallikrein occurs through
cleavage of the Arg371-Ile372 bond, producing a two-subunit protein containing a heavy chain and
1

Figure 1: The structure of prekallikrein (PK). A1 – A4 represent the four apple domains in the
N-terminal region of PK. The red arrow indicates the site of cleavage (Asp371-Ile372) of PK by
FXIIa to yield the active serine protease, kallikrein. The three black circles represent kallikrein’s
catalytic triad consisting of His415, Asp464 and Ser559. Shaded circles represent the regions
involved in binding to HK.
[Reprinted with copyright permission from Chung et al. (1986)].

a light chain linked via a single disulfide bond between Cys364 and Cys484 (Wuepper and
Cochrane, 1972) (Figure 1). The N-terminal heavy chain of 371 amino acids (53 kDa) contains
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the four apple domains (A1 – A4), the homologues of which are also found in factor XI (FXI),
whereas the C-terminal light chain of 248 amino acids (33-36 kDa) forms the protease domain
and contains the catalytic triad His415, Asp464 and Ser559 (van der et al., 1982; McMullen et al.,
1991). Crystal structure of human plasma kallikrein protease domain expressed in Picihia
pastoris and baculovirus/sf9 cells shows that it adopts a typical chymotrypsin-like serine
protease fold (Figure 2) (Tang et al., 2005). There is extensive sequence conservation between
the protease domain of plasma kallikrein and of other trypsin-like serine proteases. The sequence
encoding the protease domain of plasma kallikrein is 39% identical with that of the protease
domain of hepsin and 38% with that of bovine trypsin. However, compared to hepsin and
trypsin, plasma kallikrein shares lower sequence identity with tissue kallikreins (33%) (Tang et
al., 2005).

Figure 2: Secondary structure of plasma kallikrein protease domain. α-helix, β-sheet and the
remaining structural elements are shown in red, yellow and cyan, respectively. The plasma
kallikrein protease domain has two six-stranded β-barrels forming the substrate-binding sites.
Bound benzamidine (a reversible inhibitor of trypsin-like serine proteases), the catalytic triad
(His57, Asp102 and Ser195) and the glycosylation sites (Asn21, Asn72 and Asn113) are also shown.
[Reprinted with copyright permission from Tang et al. (2005)].
3

B. Role of Plasma Kallikrein in Inflammation
Plasma kallikrein is deeply involved in various pathological processes associated with
inflammation. First, as a component of the plasma kallikrein-kinin system (KKS), plasma
kallikrein catalyzes the enzymatic cleavage of HK to liberate the potent pro-inflammatory
peptide bradykinin (BK) (Kerbiriou and Griffin, 1979). BK upon activation of its constitutive
BK B2 (B2) receptors on endothelial cells leads to an increase in intracellular Ca2+ levels and
subsequent production of nitric oxide (NO) and prostacyclin (PGI2), ultimately leading to
vasodilation, increased vascular permeability and edema (Zhao et al., 2001; Hong, 1980; Palmer
et al., 1987) (Figure 3). Whereas B2 receptors are constitutively expressed, the expression of BK
B1 (B1) receptors is induced during inflammation (Marceau, 1995). Metabolism of BK by
carboxypeptidase N (CPN) in plasma or carboxypeptidase M (CPM) on endothelial cells yields
des-Arg9-BK which interacts with B1 receptors to potentiate and/or perpetuate the inflammatory
response (Marceau et al., 1981). Second, plasma kallikrein directly activates the alternative
complement pathway as well as catalyzes the secondary cleavage of αFXIIa to yield βFXIIa,
which can then activate the classical complement pathway (Discipio, 1982; Ghebrehiwet et al.,
1981) (Figure 3). Activation of the complement system via either of these pathways leads to the
production of chemotactic mediators such as C3a and C5a, opsonins such as C3b and the
membrane attack complex C5b-9 (Muller-Eberhard, 1988). Last, plasma kallikrein is capable of
stimulating neutrophil chemotaxis, aggregation, oxidative metabolism and neutrophil elastase
release. These effects of kallikrein on neutrophils are dependent upon the integrity of the active
site of the protease but are independent of its complement activating properties (Kaplan et al.,
1972; Schapira et al., 1982; Wachtfogel et al., 1983). Thus, existing evidence points to the role,
both direct and indirect, of plasma kallikrein in the pathogenesis of inflammation.
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Figure 3: Role of plasma kallikrein in inflammation, coagulation and fibrinolysis. HK: high
molecular weight kininogen, PK: prekallikrein, BK: bradykinin, HKa: cleaved HK, PRCP:
prolylcarboxypeptidase, tPA: tissue plasminogen activator, uPA: urokinase plasminogen
activator, FDP: fibrin degradation products.
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[Adapted and modified from Bryant et al. (2009)].
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C. Role of Plasma Kallikrein in Hemostasis and Thrombosis
HK, PK and FXII are the key components of the intrinsic (contact activation) pathway of
blood coagulation. The intrinsic pathway is initiated when FXII comes in contact with negatively
charged surfaces such as constituents of the subendothelial matrix (glycosaminoglycans and
collagen) and gets autoactivated to the active serine protease factor XIIa (αFXIIa) in a reaction
involving HK and PK (Cochrane and Griffin, 1982) (Figure 3). αFXIIa in turn activates factor XI
(FXI) to FXIa, thereby initiating a series of proteolytic reactions ultimately leading to the
production of thrombin, fibrin and clot formation (Davie and Ratnoff, 1964; Macfarlane, 1964).
Besides FXI, αFXIIa can also activate PK to plasma kallikrein on negatively charged surfaces.
However, on endothelial cells, PRCP produces kinetically favorable PK activation (Km = 6.7 nM)
than that produced by αFXIIa on negatively charged surfaces (Km = 2.4 µM) (Shariat-Madar et
al., 2002; Stavrou and Schmaier, 2010). Plasma kallikrein in turn leads to reciprocal activation of
FXII to αFXIIa, thus creating an amplification loop in the intrinsic pathway of coagulation
(Figure 3). The presence of plasma kallikrein causes FXII activation to occur ~100 times faster
as compared to its autoactivation (Cochrane and Griffin, 1979). Thus, plasma kallikrein regulates
FXII activation and initiation of the intrinsic pathway of coagulation both on negatively charged
surface (pathophysiologcal) as well as on endothelial cells (physiological).
Despite its obvious importance in blood coagulation from experimental studies, the
pathophysiological significance of the intrinsic pathway of coagulation has been questioned over
the past 50 years, based on the important clinical observation that FXII- as well as PK-deficient
patients do not exhibit abnormal bleeding despite having a prolonged activated partial
thromboplastin time (aPTT) (Ratnoff and Margolius, Jr., 1955; Hathaway et al., 1976).
Consistent with these observations in humans, experimental evidence suggests that FXII-/- mice
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have normal bleeding time and show no spontaneous bleeding, supporting the notion that unlike
extrinsic pathway, the intrinsic pathway of coagulation is dispensable for hemostasis. However,
using three different models of arterial thrombosis, Renne et al. demonstrated that FXII-/- mice
are protected against collagen- and epinephrine-induced thromboembolism (Renne et al., 2005).
Furthermore, another recent study by Cheng et al. (2010) showed that the antibody14E11, which
binds FXI thereby interfering with FXIIa-mediated FXI activation, prevented arterial occlusion
induced by FeCl3. 14E11 also had a modest beneficial effect in a tissue factor-induced
pulmonary embolism model in mice and reduced platelet-rich thrombus growth in collagencoated grafts inserted into an arteriovenous shunt in baboons. These studies suggest that although
not required for hemostasis, the intrinsic pathway of coagulation is essential for pathological
thrombus formation.
While FXIIa and FXIa are pro-thrombotic, plasma kallikrein has both pro- and antithrombotic attributes owing to its pleiotropic effects on platelet aggregation, coagulation cascade
and fibrinolytic system (Colman, 2005; Bryant and Shariat-Madar, 2009). Plasma kallikrein is a
potent activator of FXII and hence the intrinsic pathway of the coagulation system (Cochrane
and Griffin, 1979). Plasma kallikrein itself has no effect on platelet aggregation. However, at low
concentrations (~10 nM) kallikrein promotes platelet aggregation induced by ADP, collagen and
adrenaline and inhibits that induced by thrombin, arachidonic acid and Thrombofax (compound
that stimulates the synthesis of thromboxane A2). On the other hand, at high concentrations (>
100 nM) kallikrein inhibits platelet aggregation induced by all these agents (Ohde et al., 1983;
Cassaro et al., 1987; Liu et al., 2011). Further, plasma kallikrein cleaves HK to produce BK. BK
and its stable metabolite BK 1-5 also inhibit thrombin-induced platelet aggregation (Murphey et
al., 2006). In addition, BK acts on endothelial cell B2 receptors to stimulate the release of NO
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and PGI2. Both NO and PGI2 are potent inhibitors of platelet adhesion and aggregation thus
contributing to the anti-thrombotic effects of BK and kallikrein (Radomski et al., 1987b;
Radomski et al., 1987a). BK also stimulates endothelial cells to release tissue plasminogen
activator (tPA), a potent profibrinolytic agent (Brown et al., 2000; Minai et al., 2001). Similarly,
plasma kallikrein converts pro-urokinase to urokinase and plasminogen to plasmin thus
promoting clot dissolution (Ichinose et al., 1986; Colman, 1969) (Figure 3).

D. Plasma Kallikrein as a Therapeutic Target
1. Hereditary Angioedema
Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by
recurrent attacks of angioedema of the skin, respiratory and gastrointestinal tracts due to an
underlying quantitative deficiency or qualitative functional defect in C1-inhibitor (C1-INH)
(Landerman et al., 1962). C1-INH not only inhibits activated complements C1r and C1s but is
also the most important endogenous inhibitor of the plasma KKS. C1-INH inhibits autoactivation
of FXII, FXIIa-dependent activation of FXI and PK, and kallikrein-mediated BK production and
FXII activation (Pixley et al., 1985). In plasma, C1-INH forms a 1:1 stoichometric complex with
kallikrein resulting in loss of proteolytic activity of the enzyme as well as inhibitory activity of
C1-INH (Schapira et al., 1983a). Reduced C1-INH antigen or activity is the underlying defect in
patients with HAE leading to widespread activation of the plasma KKS (Table 1). Plasma
kallikrein-mediated excessive BK production is the major cause of edema and the leading cause
of morbidity in HAE patients (Schapira et al., 1983b).
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Table 1: Clinical and experimental conditions associated with activation of plasma
kallikrein-kinin system (KKS)

Disease / Experimental
Model

HK

PK

FXII

C1-INH

C1-INH-Kallikrein /
α2M-Kallikrein

Hereditary angioedema

↓

↓
̶

↓

↑

Cardiopulmonary bypass
(CPB)
̶

̶

̶

̶

↑

Sepsis

↓

↓

↓

↓

↑

Acute respiratory distress
syndrome (ARDS)

↓

↓

↓

↓

↑

Disseminated
intravascular coagulation
(DIC)
̶

↓

↓

↓
̶

HK: high molecular weight kininogen, PK: prekallikrein, FXII: coagulation factor XII, C1-INH:
C1-inhibitor.
↑ - increased, ↓ - decreased, − - not measured.
[Adapted and modified from Colman et al. (1997)].

Since the plasma KKS is central to the pathogenesis of HAE, the current therapy in
clinical use or in development for HAE is based on blocking this pathway using two basic
strategies – plasma kallikrein inhibition (using C1-INH or plasma kallikrein inhibitor) and BK
antagonism (using specific B2 receptor antagonist). The C1-INH CinryzeTM (Lev
Pharmaceuticals, Inc.) was the first drug to be approved by the US FDA in October 2008 for
chronic replacement or prophylaxis, but not for treatment, of acute attacks of HAE (Cocchio and

9

Marzella, 2009). Recently in 2009, FDA approved two new drugs – the C1-INH Berinert® (CSL
Behring) and the recombinant plasma kallikrein inhibitor ecallantide (Kalbitor®, Dyax Corp.) –
for the treatment of acute attacks of HAE in adolescents and adults (Keating, 2009; Zuraw et al.,
2010). However, the synthetic decapeptide HOE140/Icatibant (Firazyr®, Jerini AG), a potent
specific B2 receptor antagonist, although approved in Europe, is still awaiting FDA approval for
the treatment of acute HAE attacks (Cicardi et al., 2010). Although CinryzeTM, Berinert® and
Kalbitor® have shown excellent efficacy in clinical trials, the major limitations of these drugs are
high cost, risk of type I hypersensitivity reaction or anaphylaxis as well as the risk of
transmitting infectious agents with CinryzeTM and Berinert®, which are derived from human
plasma (Table 2) (Lunn et al., 2010; Riedl, 2010).

2. Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) is known to induce disseminated intravascular
coagulation (DIC), systemic inflammatory response syndrome (SIRS) and ischemia/reperfusion
(I/R) injury resulting in excessive blood loss, hypotension, increased vascular permeability,
edema and myocardial dysfunction (Mojcik and Levy, 2001; Dietrich, 2000). During CPB, there
is extensive contact between blood and the synthetic surfaces of the extracorporeal circuit. The
interaction of endothelial cells, neutrophils and platelets together with activation of the contact,
complement, coagulation and fibrinolytic systems has been implicated in the pathogenesis of
post-CPB DIC and SIRS (Campbell et al., 2001; Alex et al., 2010). In simulated CPB, there is a
significant increase in C1-INH-kallikrein and C1-INH-C1 complexes, suggesting that FXII, PK
and C1 activation is occurring ultimately leading to activation of the contact and classical
complement pathways (Table 1) (Wachtfogel et al., 1989).
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Aprotinin, a non-specific serine protease inhibitor, has been used for the past two decades
to reduce perioperative blood loss and the need for blood transfusion during cardiac surgery and
CPB. The major targets of aprotinin within the hemostatic system are plasma kallikrein, plasmin,
thrombin, tissue factor/activated FVII (TF/FVIIa) complex, activated protein C (APC) and
platelet protease activated receptor-1 (PAR-1), thus explaining its efficacy not only in reducing
blood loss but also in mitigating SIRS and I/R injury during CPB (McEvoy et al., 2007).
However, recently the marketing of aprotinin was suspended owing to severe safety
considerations (DeAnda, Jr., 2008). Several recent clinical trials comparing aprotinin with two
other anti-fibrinolytic agents, tranexamic acid and ε-aminocaproic acid, demonstrated that the
use of aprotinin is associated with serious end-organ damage including an increased risk of renal
failure, myocardial infarction, heart failure, stroke and encephalopathy (Table 2) (Mangano et
al., 2006; Jakobsen et al., 2009). In the Canadian BART study including 3000 patients
undergoing cardiac surgery, a trend towards increased mortality in the aprotinin group was
observed (Fergusson et al., 2008). Further, hypersensitivity/anaphylaxis is a serious complication
of aprotinin, especially in those re-exposed to this drug within a 6-month period (Dietrich et al.,
2007).
Since plasma kallikrein is capable of activating the contact, complement, and fibrinolytic
pathways, it is possible that a potent and selective inhibitor of this enzyme may have some utility
in controlling the widespread inflammatory and hematologic responses to CPB. Indeed, the
recombinant plasma kallikrein inhibitor ecallantide showed promising results in preclinical and
phase I/II clinical studies with 50% reduction in blood transfusion requirement in patients
undergoing coronary artery bypass graft (CABG) surgery with CPB (Lehmann, 2008). However,
two subsequent phase II clinical trials – CONSERV I and CONSERV II – in patients at low and
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Table 2: Plasma KKS as a therapeutic target

Disease /
Experimental
Model

Current Drugs
(Clinical /
Experimental)

Source

Target

Limitations

Hereditary
angioedema
(HAE)

C1-INH Cinryze™
C1-INH Berinert®

Human
plasma

Plasma kallikrein,
FXIIa, C1r, C1s

High cost,
anaphylaxis,
risk of
transmitting
infectious
agents.

DX-88 /
Ecallantide
(Kalbitor®)

Recombinant
(Host: Pichia
pastoris)

Plasma kallikrein

High cost,
immunogenicity,
anaphylaxis.

HOE140/Icatibant
(Firazyr®)

Synthetic
decapeptide

B2 receptor
antagonist

Approved in
Europe but not
in US.

Aprotinin
(Trasylol®)

Bovine lungs

Plasma kallikrein,
plasmin, thrombin,
TF/FVIIa, APC,
platelet PAR-1

Serious endorgan damage,
anaphylaxis, ↑
mortality
(withdrawn in
2007).

DX-88 /
Ecallantide
(Kalbitor®)

Recombinant
(Host: Pichia
pastoris)

Plasma kallikrein

No benefit and
↑ mortality in
phase II trials;
high cost,
immunogenicity,
anaphylaxis.

CPB

(continued…)
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Sepsis

ARDS, DIC

Activated protein
C / Drotrecogin
alfa (Xigris®)

Recombinant
(Host:
HEK293 cells)

FVa, FVIIIa, PAI-1
↓ neutrophil
chemotaxis, cytokine
production and
leucocyte-endothelial
cell interaction

Bleeding, high
cost; approved
only for severe
sepsis.

HOE140/Icatibant
(Firazyr®)

Synthetic
decapeptide

B2 receptor
antagonist

No beneficial
effect in animal
models; does
not block B1
receptors.

C1-INH Cinryze™
C1-INH Berinert®

Human
plasma

Plasma kallikrein,
FXIIa, C1r, C1s

High cost,
anaphylaxis,
risk of
transmitting
infectious
agents.

PKSI-527

Synthetic

Plasma kallikrein

No data in
humans.

Clinical and experimental drugs targeting plasma kallikrein, B2 receptors, FXIIa and/or other
related components of the coagulation, fibrinolytic or complement systems and shown to have
beneficial effects in hereditary angioedema (HAE), cardiopulmonary bypass (CPB), sepsis,
disseminated intravascular coagulation (DIC) and/or acute respiratory distress syndrome (ARDS)
are listed. The sources and limitations of these drugs are summarized. (Lehmann, 2008; DeAnda,
Jr., 2008; Riedemann et al., 2003; 2010; Feletou et al., 1996; Caliezi et al., 2002; Katsuura et al.,
1996; Uchiba et al., 1997)

high risk of bleeding complications, respectively, demonstrated no significant improvement in
blood loss. Further, in patients at high risk of bleeding, there was a statistically significant higher
rate of mortality with ecallantide as compared to tranexamic acid, leading to premature
termination of these studies (2010). However, since experimental evidence strongly points to the
involvement of plasma kallikrein in post-CPB coagulopathy and SIRS, larger, well-designed
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clinical trials in carefully characterized patients are needed to further explore and conclusively
establish the therapeutic role of plasma kallikrein inhibitors in this condition.

3. Sepsis, Acute Respiratory Distress Syndrome (ARDS) and Disseminated
Intravascular Coagulation (DIC)
Sepsis is defined as a systemic inflammatory response syndrome (SIRS) with an
underlying infection. The complex humoral and cellular response triggered by the presence of
microorganisms or their toxic products in circulation involves the release of inflammatory
mediators such as cytokines, especially interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α); arachidonic acid metabolites such as prostaglandins and
thromboxane; neutrophil proteolytic enzymes such as elastase; as well as activation of the
coagulation, fibrinolytic, complement and kallikrein-kinin systems (Bone et al., 1992; Bone,
1992; Carmona et al., 1984; Voss et al., 1989). Sepsis is also the leading cause of ARDS and
DIC. During sepsis, FXII and PK are activated to enzymes that rapidly react with C1-INH to
form C1-INH-FXIIa and C1-INH-kallikrein complexes (Colman, 1989). As functional C1-INH
levels decline, α2 macroglobulin (α2M) becomes a more important inhibitor of kallikrein leading
to formation of α2M-kallikrein complexes. Elevated levels of C1-INH-FXIIa, C1-INHkallikrein, α2M-kallikrein and inactive C1-INH, reduced levels of FXII, PK and HK, and
increased cleavage of HK with subsequent production of BK in patients with sepsis, DIC and
ARDS point to the role of plasma kallikrein in these disorders (Table 1) (Nuijens et al., 1988;
Nuijens et al., 1989; Kaufman et al., 1991; Mason and Colman, 1971; Carvalho et al., 1988).
Increased kallikrein-dependent BK production in sepsis leads to hypotension, edema and septic
shock (Katori et al., 1989). BK also stimulates bronchial epithelial cells, alveolar macrophages
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and lung fibroblasts to release pro-inflammatory cytokines and chemokines such as IL-6, IL-8,
leukotriene B4 (LTB4), platelet-activating factor (PAF), monocyte chemoattractant protein-1
(MCP-1), granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GMCSF), and transforming growth factor-β (TGF-β) thus contributing to lung inflammation and
ARDS (Sato et al., 1996; Koyama et al., 1995; Koyama et al., 2000; Hayashi et al., 2000).
One of the experimental anti-inflammatory strategies for the treatment of sepsis has been
to target the plasma KKS by blocking the effects of BK using potent B2 receptor antagonists.
However, experimental and clinical studies evaluating the effect of B2 receptor antagonists in the
treatment of sepsis and SIRS have shown controversial results. Whereas some B2 receptor
antagonists (B4148, NPC 567, NPC 17931, NPC 17647 and CP-0127) showed excellent promise
in reducing mortality and/or preventing hypotension in animal models of sepsis, a latter study by
Feletou et al. showed that the potent and specific B2 receptor antagonist HOE140 (Icatibant) had
no significant effect on the survival rate in murine and rabbit models of endotoxic shock (Table
2) (Wilson et al., 1989; Weipert et al., 1989; Prosser et al., 1991; Whalley et al., 1992; Feletou et
al., 1996). Since NPC 567 and CP-0127 also inhibit B1 receptors, it has been speculated that the
inducible B1 receptors play an important role in sepsis and the lack of beneficial effect of HOE
140 could be because of its inability to block the effects of BK at these receptors (Feletou et al.,
1996). Indeed, a recent study by Merino et al. (2008) showed that transgenic rats overexpressing
B1 receptors in the endothelium are more susceptible to LPS-induced endotoxic shock and
exhibit pronounced hypotension, marked bradycardia and increased mortality compared to nontransgenic animals . Further, another study by Otterbein et al. (1993) demonstrated that coadministration of a B2 receptor antagonist NPC 17761 and a leucocyte recruitment inhibitor NPC
15669 increased survival and inhibited leucopenia in response to a lethal dose of endotoxin in
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rats. However, the beneficial effect was lost when either drug was administered alone,
highlighting the importance of simultaneously targeting multiple pathways for the treatment of
sepsis.
Since plasma kallikrein mediates BK production; neutrophil chemotaxis, aggregation and
degranulation; and complement and coagulation pathway activation, plasma kallikrein inhibitors
could represent a novel class of drugs for the treatment of sepsis and sepsis-related
complications. Indeed, treatment with C1-INH, the major plasma inhibitor of the complement
and contact systems, has been shown to attenuate renal impairment in patients with severe sepsis
or septic shock (Caliezi et al., 2002). Similarly, the synthetic plasma kallikrein inhibitor PKSI527 has been shown to prevent changes in coagulation and fibrinolytic pathways as well as
suppress increased serum aspartate transaminase (AST) and alanine transaminase (ALT) levels
in LPS-induced DIC in rats (Katsuura et al., 1996). Further, in a subsequent study, Uchiba et al.
(1997) demonstrated that PKSI-527 prevents pulmonary vascular injury as well pulmonary
histological changes in endotoxin-treated rats; whereas DEGR-VIIa, an active-site blocked FVII,
failed to do so, suggesting that the intrinsic pathway of coagulation may be more important than
the extrinsic pathway in endotoxin-induced lung inflammation. Thus, current evidence supports
the idea that plasma kallikrein represents an important target in the treatment of sepsis and
sepsis-induced complications (Table 2).

4. Thromboembolic disorders
Formation of an occlusive thrombus at the site of endothelial damage is the key event in
the pathogenesis of acute myocardial infarction (AMI), acute ischemic stroke (AIS) and deep
vein thrombosis (DVT). Fibrinolytic agents such as recombinant tissue plasminogen activator
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(rtPA; Alteplase/Activase®) are commonly used in the treatment of AMI and AIS. However, the
major drawbacks of rtPA in the treatment of AMI are increased risk of bleeding and high
incidence of re-occlusion (Ohman et al., 1990; Alexandrov and Grotta, 2002; Agnelli, 1996;
Oldgren et al., 2010; Albers et al., 2002). Evidence suggests that recurrent thrombosis in patients
treated with rtPA is a consequence of plasmin-induced FXII and plasma kallikrein activation
leading to persistent thrombin generation during fibrinolysis (Ewald and Eisenberg, 1995).
Similarly, in AIS, tPA is effective only in 32% of eligible patients (Lansberg and Schwartz,
2009). Moreover, tPA and plasmin have been shown to promote disruption of the blood-brain
barrier leading to hemorrhagic transformation and neuronal damage in AIS (Hacke et al., 2008;
Burggraf et al., 2007; Wang et al., 1998).
Oral anticoagulants such as warfarin (Coumadin®) are effective in the prevention and
long-term treatment of DVT and pulmonary embolism (Key and Kasthuri, 2010). However,
warfarin has numerous limitations, including lack of reversibility, a steep dose response curve,
multiple food-drug and drug-drug interactions, need for monitoring the prothrombin time (PT),
and a narrow therapeutic index (Lin, 2005). The availability of newer oral anticoagulants, such
as direct and selective FXa and thrombin inhibitors, has overcome several of these limitations;
however, dose-dependent bleeding continues to remain a significant problem (Di et al., 2005;
Buller et al., 2008; Mega et al., 2009). Recent studies in FXII-/- and FXI-/- mice have shown that
the intrinsic pathway of coagulation is critical for thrombus formation but is less important for
hemostasis (Renne et al., 2005; Cheng et al., 2010). Therefore, potent and selective inhibitors of
this pathway are now being explored as novel anti-thrombotic agents that are devoid of the risk
of bleeding (Robert et al., 2008; Schumacher et al., 2010). FXIIa and FXIa inhibitors have been
evaluated in various models of arterial and/or venous thromboembolism. Hagedorn et al. (2010)
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showed that the FXIIa inhibitor, recombinant human albumin-infestin-4 (rHA-Infestin-4),
abolishes FeCl3-induced occlusive arterial thrombus formation in mice and rats while leaving
hemostasis intact. Similarly, Lin et al. (2006) demonstrated that the peptidomimetic FXIa
inhibitor, Compound 32, reduces thrombus mass in a rat model of venous thrombosis without
prolonging the bleeding time. However, FXI deficiency in humans (hemophilia C) is associated
wih mild injury-related bleeding and it remains unclear whether the lack of FXI in humans
protects against thromboembolic events (Lowenberg et al., 2010).
Since plasma kallikrein regulates FXII activation, inhibition of plasma kallikrein could
provide a novel anti-thrombotic therapeutic approach for the treatment of AMI, AIS and
DVT/pulmonary embolism. However, to date no studies have been conducted to investigate the
anti-thrombotic potential of plasma kallikrein inhibitor in these disorders, either alone or as an
adjunct to the current standard of care.

E. Objective
Plasma kallikrein plays a critical role in the pathogenesis of inflammation and thrombosis
and represents a valid target for the treatment of numerous disorders such as HAE, CPB, sepsis,
ARDS, DIC, AMI, AIS and DVT (Bryant and Shariat-Madar, 2009). Development of novel
therapeutic agents for the treatment of some of these conditions is a priority since the current
drugs have limited efficacy and/or are associated with several adverse effects (Table 2).
The primary objective of this study was to develop and characterize a novel, potent small
molecule inhibitor of plasma kallikrein and to evaluate its potential usefulness in the treatment of
kallikrein-mediated inflammatory and thrombotic disorders using in vitro, in situ and in vivo
approaches.
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II. EXPERIMENTAL METHODS

A. Kallikrein inhibition in fluid phase –
2 nM human plasma kallikrein (Enzyme Research Laboratories, South Bend, IN) was
incubated with 0.5 mM S2302 (H-D-Pro-Phe-Arg-pNA·2HCl, DiaPharma Group, Inc., West
Chester, OH) in the absence or presence of increasing concentrations of PF-04886847, PD0180988 (negative control), Kallistop (positive control) or SBTI (positive control) in a final
volume of 100 µl HEPES-NaHCO3 buffer (137 mM NaCl, 3 mM KCl, 14.7 mM HEPES, 1 mM
MgCl2, 2 mM CaCl2, 5.5 mM D-glucose and 0.1% gelatin; pH 7.1). After 1 hr of incubation at
37°C, kallikrein activity was measured as the change in absorbance at 405 nm, using BioTek
ELx800 Absorbance Microplate Reader.

B. Kallikrein inhibition kinetics of PF-04886847 –
Experiments were performed to determine whether PF-04886847 is a competitive or noncompetitive inhibitor of kallikrein. Kallikrein (0.2 nM) was incubated with increasing
concentrations (0.05 – 1 mM) of S2302 in the absence or presence of various concentrations of
PF-04886847 (0.001 – 0.3 µM) in a final volume of 100 µL HEPES-NaHCO3 buffer. Substrate
hydrolysis was allowed to proceed for 1 hr at 37°C. The velocity (V) of the reaction was
expressed as the change in absorbance at OD 405 nm (∆A) min-1· ng-1 kallikrein and was plotted
against the substrate concentration in mM. Data was analyzed using GraphPad Prism software
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(GraphPad Software, Inc.) (Lineweaver–Burk plot) to establish the inhibition pattern and to
confirm the ki of PF-04886847.

C. Endothelial cell culture –
Human pulmonary artery endothelial cells (HPAEC; Invitrogen Life Technologies,
Carlsbad, CA) were cultured in Medium 200 supplemented with low serum growth supplement
(Invitrogen Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol.

D. Kallikrein inhibition on HPAEC –
HPAEC (3 x 104 cells/well) were cultured overnight in a 96-well microtiter plate (Greiner
Bio-One, Monroe, NC). Confluent monolayers of HPAEC were washed three times with
HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37oC to prevent non-specific
binding. After washing three times with HEPES-NaHCO3 buffer, HPAEC were then incubated
with 20 nM HK (DiaPharma Group, Inc., West Chester, Ohio) for 1 hr at 37oC. At the end of
incubation, cells were washed three times with HEPES-NaHCO3 buffer to remove the unbound
HK and then treated with 20 nM PK (DiaPharma Group, Inc., West Chester, Ohio) in the
absence or presence of increasing concentrations of PF-04886847, PD-0180988, Kallistop or
SBTI. After 1 hr incubation at 37oC, cells were washed three times and 0.5 mM S2302 in 100 µl
HEPES-NaHCO3 buffer was added to determine the activity of kallikrein produced. Substrate
hydrolysis was allowed to proceed for 1 hr at 37oC. Kallikrein activity was measured as the
change in absorbance at 405 nm, using BioTek ELx800 Absorbance Microplate Reader.
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E. Effect of PF-04886847 on biotin-HK binding to HPAEC –
Binding studies were performed on HPAEC (3 x 104 cells/well) cultured overnight in 96well microtiter plate. Confluent monolayers of HPAEC were washed three times with HEPESNaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37oC. After washing three times with
HEPES-NaHCO3 buffer, HPAEC were incubated with increasing concentrations (0 – 200 nM) of
biotin-HK for 1 hr at 37oC. Biotin-HK binding to cells was determined using the peroxide
specific fast-reacting substrate, turbo 3,3’,5,5’-tetramethylbenzindine dihydrochloride (Turbo
TMB, Pierce, Rockford, IL). Cells were washed three times with HEPES-NaHCO3 buffer to
remove the unbound biotin-HK and then incubated with streptavidin horseradish peroxidase
(1:500 dilution) for 1 hr at room temperature. At the end of incubation, 100 µl of the substrate
Turbo TMB was added and allowed to develop for 10 minutes while mixing on an orbital shaker
at room temperature. The reaction was stopped by adding 1 M phosphoric acid (100 µl), and the
level of binding was determined by measuring the absorbance of the reaction mixture in each
well at OD 450 nm using BioTek ELx800 Absorbance Microplate Reader. Data was analyzed
using GraphPad Prism software (one site binding equation) to obtain the KD for biotin-HK
binding to HPAEC.
The effect of PF-04886847 on biotin-HK binding to HPAEC was determined. Confluent
monolayers of HPAEC cultured overnight in 96-well microtiter plate were washed three times
with HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37oC. After washing three
times with HEPES-NaHCO3 buffer, cells were then incubated with 20 nM biotin-HK in the
absence or presence of increasing concentrations of PF-04886847 or PD-0180988 (negative
control) for 1 hr at 37oC. Biotin-HK binding to cells was determined as described above.
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F. Effect of PF-04886847 on biotin-PK binding to HK bound to HPAEC –
Confluent monolayers of HPAEC were washed three times with HEPES-NaHCO3 buffer
and blocked with 1% gelatin for 1 hr at 37oC. After washing three times with HEPES-NaHCO3
buffer, HPAEC were incubated with increasing concentrations (0 – 200 nM) of HK for 1 hr at
37oC. At the end of the incubation, cells were washed three times with HEPES-NaHCO3 buffer
and treated with increasing concentrations (0 – 200 nM) of biotin-PK for 1 hr at 37oC. Cells were
then washed three times with HEPES-NaHCO3 buffer to remove the unbound biotin-PK and
incubated with streptavidin horseradish peroxidase (1:500 dilution) for 1 hr at room temperature.
At the end of incubation, 100 µl of the substrate Turbo TMB was added and allowed to develop
for 10 min while mixing on an orbital shaker at room temperature. The reaction was stopped by
adding 1 M phosphoric acid (100 µl), and the level of binding was determined by measuring the
absorbance of the reaction mixture in each well at OD 450 nm using BioTek ELx800
Absorbance Microplate Reader. Data was analyzed using GraphPad Prism software (one site
binding equation) to obtain the KD for biotin-PK binding to HK bound to HPAEC.
The effect of PF-04886847 on biotin-PK binding to HK bound to HPAEC was
determined. Confluent monolayers of HPAEC cultured overnight in 96-well microtiter plate
were washed three times with HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at
37oC. After washing three times with HEPES-NaHCO3 buffer, cells were then incubated with 20
nM HK for 1 hr at 37oC. At the end of the incubation, cells were washed three times with
HEPES-NaHCO3 buffer and then treated with 20 nM biotin-PK in the absence or presence of
increasing concentrations of PF-04886847 or PD-0180988 (negative control) for 1 hr at 37oC.
Biotin-PK binding to HK bound to cells was determined as described above.
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G. Effect of PF-04886847 on recombinant prolylcarboxypeptidase (rPRCP) –
80 nM rPRCP (88 µl of 0.01 mg/ml rPRCP in a total volume of 220 µl HEPES-NaHCO3
buffer) was incubated with 1 mM APpNA (Ala-Pro-p-Nitroanilide, Bachem, Torrance, CA) in
the absence or presence of increasing concentrations of PF-04886847, PD-0180988, Kallistop or
SBTI in a final volume of 100 µl HEPES-NaHCO3 buffer. After 1 hr of incubation at 37°C, the
liberation of paranitroaniline from APpNA by rPRCP was measured as the change in absorbance
at 405 nm, using BioTek ELx800 Absorbance Microplate Reader.

H. FXIa inhibition in fluid phase –
2 nM FXIa (Enzyme Research Laboratories, South Bend, IN) was incubated with 0.291
mM S2366 in the absence or presence of increasing concentrations of PF-04886847, PD0180988, Kallistop or SBTI in a final volume of 100 µl HEPES-NaHCO3 buffer. After 1 hr of
incubation at 37°C, the liberation of paranitroaniline from S2366 by FXIa was measured as the
change in absorbance at 405 nm, using BioTek ELx800 Absorbance Microplate Reader.

I. FXIa inhibition on HPAEC –
A novel assay was developed to study the effect of PF-04886847 on activity of FXIa
produced on endothelial cell surface. Confluent monolayers of HPAEC cultured overnight in a
96-well microtiter plate were washed three times with HEPES-NaHCO3 buffer and blocked with
1% gelatin for 1 hr at 37oC to prevent non-specific binding. After washing three times with
HEPES-NaHCO3 buffer, HPAEC were then incubated with increasing concentrations (0 – 600
nM) of HK for 1 hr at 37oC. At the end of incubation, cells were washed three times with
HEPES-NaHCO3 buffer to remove the unbound HK and then treated with increasing
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concentrations (0 – 300 nM) of FXI (DiaPharma Group, Inc., West Chester, Ohio). After 1 hr
incubation at 37oC, cells were washed three times and 0.5 mM S2366 (< Glu-Pro-Arg-pNA·HCl,
DiaPharma Group, Inc., West Chester, OH) in 100 µl HEPES-NaHCO3 buffer was added to
determine the activity of FXIa. Substrate hydrolysis was allowed to proceed for 1 hr at 37oC.
FXIa activity was measured as the change in absorbance at 405 nm, using BioTek ELx800
Absorbance Microplate Reader. The same assay was carried out on a 96-well microtiter plate
without HPAEC to rule out FXI autoactivation.
The above assay was used to determine the effect of PF-04886847 on FXIa activity on
HPAEC. Cells were treated with 80 nM HK followed by 40 nM FXI in the absence or presence
of increasing concentrations of PF-04886847, PD-0180988, Kallistop or SBTI. FXIa activity was
measured using as described above.

J. Changes in intracellular Ca2+ levels in HPAEC in response to HK-FXI –
To confirm FXI activation on endothelial cell surface, changes in [Ca2+]i levels in
HPAEC in response to treatment with HK-FXI complex were measured using confocal
microscopy. Monolayers of HPAEC seeded on cover slips were loaded with 10 µM Fluo-4 AM
(Invitrogen Life Technology, Carlsbad, CA). The cover slips were mounted on a perfusion
chamber (Warner Instruments, Hamden, CT) and were continuously perfused with HEPESbuffer from a perfusion pump driven system at a rate of 1 mL/min. Cells were then treated with
various concentrations of HK+FXI in 2:1 ratio. Fluorescence in a microscope field containing 10
to 30 cells was imaged using LSM 510 software. Changes in [Ca2+]i levels were measured as
changes in fluorescence at an excitation wavelength of 488 nm and an emission wavelength of
505 nm using a Zeiss LSM 510 META confocal microscope. At the end of each experimental
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run, cells were perfused with 1 µM ionomycin solution (a Ca2+ ionophore) to obtain the maximal
fluorescence intensity.

K. FXIIa inhibition in fluid phase –
20 nM FXIIa (Enzyme Research Laboratories, South Bend, IN) was incubated with 0.5
mM S2302 (H-D-Pro-Phe-Arg-pNA·2HCl) in the absence or presence of increasing
concentrations of PF-04886847, PD-0180988, Kallistop or SBTI in a final volume of 100 µl
HEPES-NaHCO3 buffer. After 1 hr of incubation at 37°C, the liberation of paranitroaniline from
S2302 by FXIIa was measured as the change in absorbance at 405 nm, using BioTek ELx800
Absorbance Microplate Reader.

L. Effect of PF-04886847 on other serine proteases of the coagulation and fibrinolytic
pathways –
The effect of PF-04886847 on thrombin, tissue factor/activated factor VII (TF/FVIIa)
complex, activated factor IX (FIXa), activated factor X (FXa), activated protein C (APC),
trypsin, plasmin and tissue plasminogen activator (tPA) was determined using substrates specific
for each of these serine proteases. Substrates for the selectivity assays were used at final
concentrations equal to their respective KM’s. The final concentrations of the serine proteases
used corresponded to the concentration that produced a 5 fold increase in the absorbance and
remained linear for at least 30 minutes. PF-04886847 concentrations ranged from 2.4 nM to 75.0
µM in half-log, 10-point serial dilutions. 105 µl of buffer containing the enzyme was added to
each well along with 2.5 µl of inhibitor and incubated for 20 minutes at 37oC while shaking. The
reactions were initiated by the addition of 20 µl of the enzyme’s respective substrate preheated to
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37°C. The change in absorbance was followed on either a Spectrmax 190 or Spectrmax Gemini
XS plate reader (Molecular Devices Corp., Sunnyvale, CA) depending on the substrate.
Concentration curves were run in triplicate and IC50 values were calculated using the 4-parameter
logistic curve fitting equation. ki values were determined using the Cheng-Prusoff equation.

M. Effect of PF-04886847 on kallikrein-dependent BK production in HPAEC –
Confluent monolayers of HPAEC cultured overnight in a 96-well microtiter plate were
washed three times with HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37oC to
prevent non-specific binding. After washing three times with HEPES-NaHCO3 buffer, HPAEC
were then incubated with 100 nM HK for 1 hr at 37oC. At the end of incubation, cells were
washed three times with HEPES-NaHCO3 buffer and treated with 100 nM PK in the absence or
presence of 10 µM PF-04886847 or PD-0180988 (negative control) together with 1 µM lisinopril
(angiotensin converting enzyme (ACE) inhibitor) and 1 µM HOE140 (B2 receptor antagonist).
After 1 hr incubation at 37ºC supernatants from each well were collected and either frozen at -70
o

C or immediately deproteinized with trichloroacetic acid. BK level in the samples was

determined using a commercial kit (MARKIT BK, Dainippon Pharmaceutical; Osaka, Japan),
according to the manufacturer’s protocol.

N. Effect of PF-04886847 on HK-PK-induced increase in intracellular Ca2+ level in
HPAEC –
Monolayers of HPAEC seeded on cover slips were loaded with the ratiometric
fluorescence Ca2+ dye Fura-2 AM (10 µM) for 30 minutes at 37ºC. Cells were then washed three
times with HEPES buffer (126 mM NaCl, 5 mM KCl, 0.3 mM NaH2PO4, 10 mM HEPES, 1 mM
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MgCl2, 2 mM CaCl2, 10 mM D-glucose; pH 7.4). The cover slips were mounted on a perfusion
chamber (Warner Instruments, Hamden, CT) and were continuously perfused with HEPES
buffer at a rate of 1 mL/min using a perfusion pump driven system. The perfusion rate was
controlled by a multichannel ValveBand computerized system connected to pinch valves
(Automate Scientific, Berkeley, CA). Cells were then treated with 300 nM HK after which 300
nM PK was injected in the perfusion line in the absence or presence of 10 µM PF-04886847.
HPAEC treated with 300 nM BK in the absence or presence of 1 µM HOE140 (Peninsula
Laboratories, San Carlos, CA), a B2 receptor antagonist, served as control. Changes in [Ca2+]i
levels were measured as changes in the fluorescence ratio at 340/380 excitation wavelength
using a dual excitation digital Ca2+ imaging system (Ionoptix Inc., Milton, MA, U.S.A). A
microscope field with no cells was chosen as background and used to generate records of the
340:380 ratio in each cell within the microscope field. At the end of each experiment, cells were
perfused with 1 µM ionomycin solution (a Ca2+ ionophore) to obtain the maximal fluorescence
intensity.

O. Effect of PF-04886847 on HK-PK-induced nitric oxide (NO) production in endothelial
cells –
Confluent monolayers of HPAEC cultured overnight in 96-well microtiter plate were
washed three times with HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37 ºC.
After washing three times with HEPES-NaHCO3 buffer, cells were then incubated with 300 nM
HK for 1 hr at 37 ºC. At the end of incubation, cells were washed three times with HEPESNaHCO3 buffer and treated with 300 nM PK in the absence or presence of 30 µM PF-04886847
and incubated for 5 minutes at 37ºC. Supernatant from each well was collected to measure the
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amount of nitrate + nitrite (the final products of NO metabolism) using a fluorometric assay
(Cayman Chemicals, Ann Arbor, MI) according to the manufacturer’s protocol.
Briefly, 10 µl of sample was added to 96-well assay plate and the volume adjusted to 80
µl using the assay buffer. The samples were then incubated at room temperature for 1 hr with 10
µl of nitrate reductase enzyme and 10 µl of enzyme cofactors to convert the nitrate to nitrite. 10
µl of DAN (2, 3-diaminonaphthalene) reagent was added to each well followed by 10 minutes
incubation at room temperature. Finally, 20 µl NaOH was added to enhance the detection of the
fluorescent product, 1(H)-naphthotriazole. The fluorescence was read at an excitation
wavelength of 360 nm and an emission wavelength of 460 nm using BioTek Synergy HT MultiMode Microplate Reader. The amount of nitrate + nitrite in each sample was calculated
according to the manufacturer’s instructions.

P. Effect of PF-04886847 on HK-PK-induced prostacyclin (PGI2) production in
endothelial cells –
Confluent monolayers of HPAEC cultured overnight in 96-well microtiter plate were
washed three times with HEPES-NaHCO3 buffer and blocked with 1% gelatin for 1 hr at 37 ºC.
After washing three times with HEPES-NaHCO3 buffer, cells were then incubated with 300 nM
HK for 1 hr at 37 ºC. At the end of incubation, cells were washed three times with HEPESNaHCO3 buffer and treated with 300 nM PK in the absence or presence of 30 µM PF-04886847.
After 1 hr incubation at 37ºC, supernatant from each well was collected to measure the amount
of 6-keto prostaglandin F1α (a stable analog of prostacyclin) in each sample using a competitive
acetylcholinesterase (AChE) enzyme immunoassay (Cayman Chemicals, Ann Arbor, MI)
according to the manufacturer’s protocol.
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Briefly, 50 µl of sample was added to 96-well microtiter plate pre-coated with mouse
monoclonal anti-rabbit IgG, followed by 50 µl of AChE conjugated 6-keto PGF1α tracer and 50
µl of 6-keto PGF1α-specific rabbit antiserum. After incubating the plate for 18 hrs at 4 ºC, the
solution was discarded and the wells washed five times with a wash buffer containing 0.05 %
Tween 20. 200 µl of Ellman’s Reagent containing the color producing substrate for AChE was
then added to each well and the plate was allowed to develop in the dark for 90-120 min. The
absorbance was measured spectrophotometrically at 405 nm using BioTek ELx800 Absorbance
Microplate Reader. The data was analyzed using a computer spreadsheet provided on the
manufacturer’s website (www.caymanchem.com/analysis/eia).

Q. Effect of PF-04886847 on HK-PK-mediated increase in HPAEC monolayer
permeability in vitro –
The effect of PF-04886847 on HK-PK-induced increase in endothelial cell monolayer
permeability was determined using an in vitro vascular permeability assay kit
(Chemicon/Millipore, Billerica, MA) according to the manufacturer’s protocol. Briefly, collagen
coating solution in 0.2X PBS, pH 7.1 was added to specialized inserts having semi-permeable
membrane at the bottom. After incubating for 1 hr at room temperature, the inserts were hydrated
with cell growth medium for 15 minutes and seeded with 200 µl of cell suspension (1.0 x 106
HPAEC/ml). The plate was incubated at 37ºC for 24 hrs until a cell monolayer was formed. The
inserts were then treated with cell basal medium (negative control), 1 µg/ml lipopolysaccharide
(LPS; positive control) or HK-PK (300 nM each) in the absence or presence of 30 µM PF04886487 and then incubated at 37ºC for 18 hrs. At the end of incubation, the solution from each
insert was removed and the inserts transferred to a permeability detection plate. 500 µl of cell
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basal medium was added to each plate well and 150 µl of 1:20 FITC-Dextran was added to each
insert. After 5 minutes of incubation at room temperature the reaction was stopped by removing
the inserts from the wells. 100 µl of the plate well solution was then transferred to a 96-well
Greiner Microlon 200 Black fluorescence detection plate (USA Scientific, FL). The effect on
HPAEC monolayer permeability was quantified by measuring the fluorescence of the solution at
an excitation wavelength of 485 nm and an emission wavelength of 528 nm using BioTek
Synergy 2 Multi-Mode Microplate Reader.

R. Effect of PF-04886847 on HK-PK-induced relaxation of lipopolysaccharide (LPS)treated isolated rat aorta precontracted by phenylephrine (PE) –
The potential value of PF-04886847 in blocking HK-PK-induced relaxation of untreated
and LPS-treated rat aorta pre-contracted with phenylephrine (PE) was determined. Rats were
treated with LPS (1 mg/kg) to induce inflammation. Part of the thoracic aorta was rapidly
harvested and dissected into 2-3 mm segments without branches according to the protocol of
Serraf. The aortic rings were then mounted on a Radnoti Tissue Bath System (Radnoti LLC,
Monrovia, CA). The aortic rings were allowed to equilibrate with LPS (1 µg/ml) in the absence
or presence of PF-04886847 (20 µM) for 2 hrs while changing the chamber solution at 15
minutes intervals. After resting tension of each aortic ring was stabilized, a sustained and stable
contraction of 1.5 g was maintained by adding 10 µM PE. The anti-inflammatory property of PF04886847 was determined by measuring the change in aortic ring tension in response to
increasing concentrations (0 – 100 nM) of the HK-PK complex.
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S. Rat model of lipopolysaccharide (LPS)-induced sepsis, ARDS and DIC –
All animal care and experimental procedures conformed to the principles of the National
Institutes of Health ‘Guide for the Care and Use of Laboratory Animals’ and were approved by
the University of Mississippi Institutional Animal Care and Use Committee. All experiments
were performed using male Sprague Dawley rats (10 – 12 weeks/300 – 400 g; Harlan
Laboratories, Inc., Prattville, AL) housed under standard environmental conditions (12/12 hr
day/night cycle at 21 ºC) and maintained on commercial rodent chow and tap water ad libitum.
After ≥ 7 days of acclimatization, animals were divided into the following experimental groups –
Control (n = 10), PF-04886847 (n = 4), DMSO/vehicle (n = 3), DMSO + LPS (n = 10), PF04886847 + LPS (n = 10) and Indomethacin + LPS (n = 5).
PF-04886847 (5 mg/ml) and Indomethacin (5 mg/ml) were dissolved in 99.7% DMSO
(Sigma-Aldrich, St Louis, MO). LPS (E. coli O111:B4; 5 mg/ml) was dissolved in sterile filtered
pyrogen-free water (Sigma-Aldrich, St Louis, MO).
Drug and LPS administration. Animals were anesthetized using intraperitoneal (i.p.)
injection of sodium pentobarbital 50 mg/kg (Sigma-Aldrich, St Louis, MO) and placed on a Far
Infrared warming pad (Kent Scientific Corporation, Torrington, CT) to maintain normal body
temperature (37 ± 1ºC). Animals were pre-treated with sterile water (control), DMSO, PF04886847 1 mg/kg or Indomethacin 1 mg/kg in a total volume of 0.2 ml i.v. through the lateral
tail vein. Since lung injury following i.v. LPS alone is associated with only mild intra-alveolar
neutrophilic infiltrates, a combination of intranasal (i.n.) and i.v. administration was used to
augment the lung injury (Matute-Bello et al., 2008). 30 minutes after drug treatment, animals
were held in an upright position and 20 µg/40 µl LPS was administered via i.n. instillation by
placing 20 µl in each nare using a sterile ultra-fine pipette tip. This was followed by LPS 10
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mg/kg administered i.v. via the lateral tail vein. The dose of LPS was selected based on previous
studies (Wang et al., 1999; Lee et al., 2001; Kao et al., 2006; Katsuura et al., 1996). Control
animals received equal volume of sterile water instead of LPS via both i.n. and i.v. routes.
Animals were allowed to recover completely from anesthesia and returned to their cages with
free access to food and water. Mortality due to all causes (anesthesia, disease induction etc.) was
0 in control, PF-04886847 and DMSO groups; 2 in DMSO + LPS group; 2 in PF-04886847 +
LPS group and 1 in Indomethacin + LPS group. Additional animals were not added to make up
the original number.
Rectal temperature and bleeding time (BT) measurements. 6 hrs post-LPS
administration, animals were anesthesized using i.p. injection of sodium pentobarbital (50
mg/kg). Rectal temperature was recorded using RET-2 Thermocouple rectal probe connected to
TH-5 Thermalert Monitoring Thermometer (Physitemp Instruments, Inc., Clifton, NJ). BT was
then determined using the tail tip transection technique (Dejana et al., 1979). Briefly, 2-3 mm tip
of the tail was cut using a surgical blade. The tail was held in a horizontal position and the tip
immersed in normal saline at 37ºC in a petri dish. The time required for complete cessation of
bleeding was recorded as the BT. A maximum observation time of 600 s. was set as the cut-off at
which the procedure was terminated. BT > 600 s. was considered to be equal to 600 s. for
statistical analysis. Additional dose of sodium pentobarbital (100 mg/kg) was then administered
i.p. to euthanize the animals.
Plasma preparation, hematology and clinical chemistry. Blood samples were
collected by cardiac puncture immediately following euthanasia. Plasma was prepared from 3 ml
of blood anticoagulated with 3.8% Na citrate (1:9 ratio) and centrifuged at 3000 g x 15 min at
23ºC. Plasma was stored at -80ºC until analysis. Blood samples were also collected in Capiject
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Capillary Blood Collection Tubes containing EDTA or lithium heparin (Terumo
Corporation/Fisher Scientific, Pittsburgh, PA). Complete blood count and comprehensive
metabolic panel were obtained using VetScan HM2 Hematology System and VetScan VS2
(Abaxis, Union City, CA), respectively.
Brochoalveloar lavage (BAL). BAL was performed to evaluate inflammatory cell
infiltration in the alveolar spaces (n = 5/group). Trachea was exposed via a mid-cervical incision
and cannulated using a disposable plastic cannula. BAL was performed by irrigating the airways
two times with 5 ml of 0.01M phosphate buffered saline (PBS, pH 7.4) at 4ºC. Typically, 7 – 8
ml of BAL fluid could be recovered. The BAL fluid was then centrifuged at 170 g for 10 minutes
at 4ºC to obtain the cell pellet. The cell pellet was re-suspended in 0.5 ml of PBS. Total
leukocyte count was determined using a Z1 Coulter Counter, Dual Threshold Analyzer
(Beckman Coulter, Brea, CA). Cells between 8 – 20 µM were counted to include WBCs and
macrophages and exclude RBCs and platelets.
Measurement of plasma TNF-α levels. Plasma TNF-α levels in representative samples
from each group were determined using a Rat TNF-α ELISA Kit (Thermo Scientific/Pierce,
Rockford, IL) according to the manufacturer’s instructions. 50 µl of pre-treatment buffer and 50
µl of standards or diluted (1:1) plasma samples were added to a 96-well microtiter plate precoated with anti-rat TNF-α antibody and incubated at 24ºC for 1 hr. The wells were then washed
four times with 1X wash buffer (200 µl/well). 50 µl of biotin-conjugated anti-rat TNF-α antibody
solution was then added to each well and incubated at 24ºC for 1 hr. Wells were washed four
times to remove unbound antibody and 100 µl of horseradish peroxidase (HRP)-labeled
streptavidin solution was added to each well and incubated for 30 minutes at 24ºC. After
washing the wells, 100 µl of TMB was added to each well and the plate developed in dark at
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24ºC for 10 minutes. The reaction was then stopped by adding 100 µl of 0.16 M sulfuric acid to
each well and the absorbance measured at 450 nm using BioTek Synergy 2 Multi-Mode
Microplate Reader. The amount of TNF-α (pg/ml) in each sample was determined from the
standard curve.
Measurement of plasma 6-keto PGF1α levels. Plasma levels of 6-keto PGF1α (a stable
analog of prostacyclin) in representative samples from each group were measured using a
competitive acetylcholinesterase (AChE) enzyme immunoassay (Cayman Chemicals, Ann
Arbor, MI) as described earlier in methods.
Measurement of plasma fibrinogen levels. Fibrinogen levels in representative plasma
samples from each group were determined using a Rat Fibrinogen ELISA Kit (Life Diagnostics,
Inc., West Chester, PA) according to the manufacturer’s protocol. Briefly, 100 µl of standards or
diluted (1:100,000) plasma samples were added to a 96-well microtiter plate pre-coated with
anti-rat fibrinogen antibody and incubated on an orbital shaker at 125 rpm at 23ºC. After 30
minutes, samples were discarded and the wells washed 8 times with 1X wash buffer (200
µl/well). 100 µl of HRP-labeled anti-rat fibrinogen antibody solution was then added to each
well and incubated at 23ºC for 30 minutes. Wells were washed to remove unbound HRP-labeled
antibodies and 100 µl of TMB reagent was then added to each well and incubated in dark for 20
minutes at 23ºC. The reaction was stopped by the addition of 100 µl of 1 M hydrochloric acid
per well and the change in color measured spectrophotometrically at 450 nm using BioTek
Synergy 2 Multi-Mode Microplate Reader. Fibrinogen concentration (mg/ml) in each sample
was determined using the standard curve.
Measurement of plasma D-dimer levels. Plasma D-dimer levels in representative
samples were measured using a Rat D-dimer ELISA Kit (Cosmo Bio USA, Carlsbad, CA),
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according to the manufacturer’s instructions. 100 µl of standards or undiluted plasma samples
were added to a 96-well microtiter plate pre-coated with an anti-rat D-dimer antibody and
incubated for 2 hrs at 37ºC. Samples were then discarded and 100 µl of biotin-conjugated anti-Ddimer antibody solution was added to each well. After 1 hr of incubation at 37 ºC, the solution
was discarded and wells washed three times with 200 µl of 1X wash buffer. 100 µl of HRPconjugated avidin solution was then added to each well and incubated at 37 ºC for 1 hr. The
wells were washed five times to remove unbound avidin and 100 µl of TMB substrate was added
to each well. The enzyme-substrate reaction was allowed to proceed at 37ºC for 10 minutes. The
reaction was terminated using 50 µl of Stop Solution (sulfuric acid). The change in color was
measured spectrophotometrically at 450 nm using BioTek Synergy 2 Multi-Mode Microplate
Reader. D-dimer concentration (ng/ml) in each sample was determined using the standard curve.

T. Balloon-induced femoral artery injury model of thrombosis in hypercholesterolemic
rabbits –
The experiments described in this section were conducted by the research team at
CVMED laboratory, Pfizer Global Research and Development. The animal model that was used
has been described previously in detail (Chi et al., 2004) (Figure 4). Male New Zealand White
rabbits were divided into 4 experimental groups – vehicle control, PF-04886847 0.1 mg/kg, 0.3
mg/kg, and 1 mg/kg (n = 5/group). Rabbits were fed a high cholesterol diet containing 2%
cholesterol and 6% hydrogenated coconut oil (Research Diets Inc., New Brunswick, NJ). One
week after beginning the high-cholesterol diet, endothelial injury was induced in the femoral
arteries of the rabbits as follows. Animals were anesthetized using i.p. ketamine (50 mg/kg) and
xylazine (6 mg/kg) and the anesthesia was maintained throughout the procedure with 1-1.5%
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isoflurane. Skin incision was made in the hind leg to expose the saphenous artery. Following an
arteriotomy, a 2-F arterial embolectomy catheter (Baxter Healthcare Corp., Irvine, CA) was
introduced into the saphenous artery and advanced retrograde into the femoral artery. The
catheter balloon was inflated with 0.07-0.1 mL normal saline, pulled back to the bifurcation of
the femoral artery and then deflated. This procedure was repeated two more times after which the
catheter was removed and the saphenous artery ligated. The procedure was performed on the
contralateral limb. This type of endothelial damage, together with the high-cholesterol diet
induces formation of a localized atherosclerotic plaque. Post-operatively, rabbits continued to
receive high-cholesterol diet for another 3 weeks.
Three weeks after the initial femoral artery injury, acute plaque rupture and thrombus
formation was induced by a second balloon injury. After anesthesia, blood samples were
collected to determine baseline coagulation parameters (prothrombin time, PT and activated
partial thromboplastin time, aPTT). Baseline bleeding time (BT) was determined using the ear
bleeding time technique. Femoral vein was cannulated for i.v. drug administration. The
previously injured segment of the femoral artery containing the atherosclerotic plaque was
isolated. A distal arteriotomy was performed and a 3-F arterial embolectomy catheter introduced
into the injured segment. Acute plaque rupture was induced by repeatedly inflating and deflating
the catheter balloon for a total of three times. The catheter was then removed and the femoral
artery ligated proximal to the arteriotomy. The proximal clamp was released allowing the artery
to reperfuse for approximately 10 seconds, following which the artery was ligated proximally to
create stasis. Vehicle or PF-04886847 was administered i.v. in a total volume of 2 mL over a 3minute period starting halfway through the acute plaque rupture and ending at stasis. After 15
minutes of stasis, the injured segment of the artery was removed, cut longitudinally and blotted.
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The thrombus was extracted from the vessel and weighed to determine the thrombus mass. Postdrug infusion blood samples were collected to determine PT and aPTT. Post-drug infusion BT
was determined using the ear bleeding time technique.

Thrombus formation

Induction of localized atherosclerotic plaque
Endothelial Injury

Weeks

0

1

Normal
Diet

Plaque Rupture

2

3

4

Drug infusion
(3 minutes)

Stasis
(15 minutes)

High Cholesterol Diet
(2% cholesterol + 6% hydrogenated coconut oil)

Figure 4: Experimental protocol for balloon-induced femoral artery injury model of
thrombosis in hypercholesterolemic rabbits. Rabbits were fed high cholesterol diet for 4
weeks and subjected to femoral artery endothelial injury to induce formation of a localized
atherosclerotic plaque. After 4 weeks, the plaque was ruptured using a balloon angioplasty
catheter to induce thrombus formation. Vehicle or PF-04886847 (0.1, 0.3 or 1 mg/kg) was
administered as an i.v. infusion in a total volume of 2 mL over a 3-minute period starting
halfway through the acute plaque rupture and ending at stasis. After 15 minutes of stasis, the
injured segment of the artery was removed and the thrombus was extracted and weighed to
determine the thrombus mass.
[Adapted and modified with permission from Chi et al. (2004)].

U. Statistical analysis –
Results are expressed as mean ± standard error of the mean (SEM) of n determinations.
In vitro experiments were performed at least three times in duplicates or triplicates. Data was
analyzed using one-way analysis of variance (ANOVA) with Newman-Keul’s or Dunnett’s posthoc test to assess statistical significance of the observed differences between drug-treated and
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corresponding control groups. For all comparisons, statistical significance was defined as P <
0.05.
For inhibition studies, data was analyzed using GraphPad Prism software (nonlinear
regression – one site competition equation) and ki determined using the Cheng-Prusoff equation.
Two representative concentrations (IC50 and absolute inhibition) of PF-04886847 were chosen
for statistical analysis. PF-04886847, SBTI and Kallistop were compared with PD-0180988
(negative control) using Dunnett’s post-hoc test.
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III. RESULTS

A. Identification of a novel plasma kallikrein inhibitor –
In order to identify a novel small molecule inhibitor of plasma kallikrein, a highthroughput screening consisting of a library of 2.2 million compounds was conducted at Pfizer,
Inc. From this screening, PF-04886847 (M.W. 589 Da) was identified as a novel inhibitor of
plasma kallikrein (Table 3).

B. PF-04886847 is a potent small molecule inhibitor of plasma kallikrein –
To determine the potency of PF-04886847 in inhibiting plasma kallikrein, the effect of
this novel compound on kallikrein activity was studied both in fluid phase and on endothelial cell
surface. PD-0180988, a known endothelin A receptor antagonist, was used as a negative control
due to its similar physical and chemical properties (Table 3). Kallistop and soybean trypsin
inhibitor (SBTI), the known inhibitors of plasma kallikrein, were used as positive controls. In
fluid phase, PF-04886847 blocked the release of paranitroaniline from S2302 (0.5 mM) by
kallikrein (2 nM) with a ki of 0.009 µM, whereas PD-0180988 had no effect. Compared to PF04886847, SBTI and Kallistop were less effective in inhibiting kallikrein activity (ki values of
0.017 µM and 4.4 µM, respectively) (Figure 5). Further, kinetic studies showed that PF04886847 is a competitive inhibitor of plasma kallikrein at a concentration ranging from 0.001 –
0.03 µM (Figure 6).
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Table 3: Chemical structure and properties of the novel plasma kallikrein inhibitor PF04886847

Compound

PF-04886847

Structure

M.W. (Da)

LogD @ pH 6.5

NH2

589

3.25

517

2.61

HN

O
N

F

N
O

N
H
F

O

OH

PD-0180988

LogD: partition coefficient
[Reprinted with copyright permission from Kolte et al. (2011)]
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S2302 hydrolysis
(OD 405 nm)

0.8
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0.6
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1000
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Figure 5: PF-04886847 inhibits kallikrein activity in fluid phase. The liberation of
paranitroaniline from S2302 (0.5 mM) by kallikrein (2 nM) in the presence of increasing
concentrations of PF-04886847, PD-0180988, Kallistop and SBTI was measured as the change
in absorbance at 405 nm after 1 hr incubation at 37ºC. Data are expressed as mean ± SEM (n = 912). *** P < 0.001 versus PD-0180988.
[Reprinted with copyright permission from Kolte et al. (2011)]

Next, the ability of PF-04886847 to inhibit kallikrein produced as a result of PK
activation on endothelial cell surface was determined. Since PF-04886847 could be directly toxic
to endothelial cells, the effect of PF-04886847 on endothelial lactate dehydrogenase (LDH) level
was initially determined. LDH levels were unaffected at 100 µM PF-04886847 (a concentration
more than 10,000 times greater than the inhibitory constant), suggesting that PF-04886847 is not
cytotoxic to endothelial cells. HPAEC were treated with 20 nM HK followed by 20 nM PK in
the presence of increasing concentrations of the compounds. SBTI and PF-04886847 blocked the
hydrolysis of S2302 by kallikrein produced on HPAEC with ki values of 0.03 µM and 0.3 µM,
respectively (Figure 7). On the other hand, both Kallistop and PD-0180988 were only weakly
effective in inhibiting the activity of kallikrein produced on HPAEC even at a concentration of
100 µM. Thus, PF-04886847 was identified as a novel, potent small molecule inhibitor of
kallikrein.
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Figure 6: Kallikrein inhibition kinetics of PF-04886847. Plasma kallikrein (0.2 nM) was
incubated with increasing concentrations (0.05 – 1 mM) of S2302 in the absence or presence of
PF-04886947 (0.001 – 0.03 µM). Substrate hydrolysis was allowed to proceed for 1 hr at 37°C.
The velocity (V) of the reaction was expressed as the change in absorbance at OD 405 nm (∆A)
min-1· ng-1 kallikrein and was plotted against the substrate concentration in mM.
[Reprinted with copyright permission from Kolte et al. (2011)]

C. PF-04886847 is a selective inhibitor of plasma kallikrein –
The assembly and activation of the HK-PK complex on endothelial cells is mediated via
binding of HK to a multiprotein cell membrane complex consisting of cytokeratin 1 (CK1),
urokinase plasminogen activator receptor (uPAR) and complement C1q receptor (gC1qR)
(Joseph et al., 1999; Mahdi et al., 2001). Since at least 75% of PK circulates in the plasma as a
complex with HK, HK serves as an acquired receptor for the binding of PK to endothelial cells.
PK is then converted to kallikrein by the constitutively expressed serine protease PRCP on
endothelial cell surface (Shariat-Madar et al., 2002). To establish the selectivity of PF-04886847
for kallikrein, the effect of this compound on the assembly and activation of the HK-PK complex
on endothelial cells was studied. Biotin labeled HK (biotin-HK) was used to determine the effect
of PF-04886847 on HK binding to endothelial cells. Biotin-HK bound to HPAEC with a high
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affinity (KD = 10 nM) (Figure 8A). When HPAEC were incubated with 20 nM biotin-HK in the
presence of increasing concentrations of PF-04886847 or PD-0180988, the binding of biotin-HK
to HPAEC was unaffected, suggesting that PF-04886847 does not interfere with this process
(Figure 8B).
A similar approach using biotin-labeled PK (biotin-PK) was used to investigate whether
PF-04886847 inhibits the binding of PK to HK on endothelial cells. Biotin-PK bound to HPAEC
pre-incubated with HK in a dose-dependent manner with a high affinity (KD = 4 nM) (Figure
9A). The binding was unaffected in the presence of increasing concentrations of PF-04886847,
suggesting that this compound does not inhibit PK binding to HK on endothelial cells (Figure

% kallikrein activity
on HPAEC

9B).
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Figure 7: Effect of PF-04886847 on endothelial cell-surface mediated PK activation. Human
pulmonary artery endothelial cells (HPAEC) were treated with 20 nM HK followed by 20 nM
PK in the absence or presence of increasing concentrations of PF-04886847, PD-0180988,
Kallistop or SBTI. The activity of kallikrein produced was determined by addition of 0.5 mM
S2302. Substrate hydrolysis was allowed to proceed for 1 hr at 37ºC. Kallikrein activity was
measured as the change in absorbance of the reaction mixture at 405 nm. Data are expressed as
mean ± SEM (n = 9). ** P < 0.01, *** P < 0.001 versus PD-0180988.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Figure 8: Effect of PF-04886847 on biotin-labeled HK (biotin-HK) binding to HPAEC.
Panel A. HPAEC were incubated with increasing concentrations of biotin-HK in HEPESNaHCO3 buffer at 37ºC for 1 hr. The binding of biotin-HK to cells was determined using
ImmunoPure streptavidin horseradish peroxidase (1:500) and peroxide specific fast-reacting
substrate, turbo-3,3’,5,5’-tetramethylbenzindine dihydrochloride (Turbo-TMB). The reaction
was stopped by adding 1 M phosphoric acid (100 µL) and the level of binding was determined
by measuring the absorbance of the reaction mixture in each well at OD 450 nm. Data are
presented as mean ± SEM (n = 9). Panel B. HPAEC were treated with 20 nM biotin-HK in the
presence of increasing concentrations of PF-04886847 or PD-0180988. Biotin-HK binding was
determined as described in Panel A.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Figure 9: Effect of PF-04886847 on biotin-labeled PK (biotin-PK) binding to HK bound to
HPAEC. Panel A. HPAEC pre-treated with increasing concentrations of HK were incubated
with equivalent concentrations of biotin-PK in HEPES-NaHCO3 buffer at 37ºC for 1 hr. The
binding of biotin-PK to cells was determined using ImmunoPure streptavidin horseradish
peroxidase (1:500) and peroxide specific fast-reacting substrate, turbo-3,3’,5,5’tetramethylbenzindine dihydrochloride (Turbo-TMB). The reaction was stopped by adding 1 M
phosphoric acid (100 µL) and the level of binding was determined by measuring the absorbance
of the reaction mixture in each well at OD 450 nm. Data are presented as mean ± SEM (n = 9).
Panel B. HPAEC pre-treated with 20 nM HK were incubated with 20 nM biotin-PK in the
presence of increasing concentrations of PF-04886847 or PD-0180988. Biotin-PK binding was
determined as described in Panel A.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Since PK activation to kallikrein on endothelial cells is mediated by PRCP, experiments
were performed to determine whether PF-04886847 inhibits PRCP activity. Recombinant human
PRCP (rPRCP) expressed in Schneider S2 insect cells derived from Drosophila melanogaster
was used in these experiments. As described in methods, 80 nM rPRCP was incubated with 1
mM APpNA in the presence of increasing concentrations of the compounds. None of the
compounds, including PF-04886847 inhibited the release of paranitroaniline from APpNA by

% rPRCP activity

rPRCP (Figure 10).
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Figure 10: Effect of PF-04886847 on recombinant human prolylcarboxypeptidase (rPRCP)
activity. 80 nM rPRCP was incubated with 1 mM APpNA in the presence of increasing
concentrations of PF-04886847, PD-0180988, Kallistop or SBTI for 1 hr at 37ºC. rPRCP activity
was determined by measuring the liberation of paranitroaniline from APpNA, quantified as the
change in absorbance at 405 nm. Data are expressed as mean ± SEM (n = 9). The absence of
standard error bars indicates that the variation was too small to be visualized.
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In order to further characterize the selectivity of PF-04886847, the effect of this novel
compound on other serine proteases of the coagulation and fibrinolytic pathways was
determined. Since plasma kallikrein shares structural similarities with FXIa, it is possible that
PF-04886847 could also inhibit FXIa. Therefore, we studied the effect of this compound on FXIa
activity both in fluid phase and on endothelial cell surface. In fluid phase, both PF-04886847 and
SBTI blocked FXIa activity with ki values of 1 µM and 0.7 µM, respectively. Kallistop also
inhibited FXIa with a ki of 24.8 µM, whereas PD-0180988 had no effect (Figure 11).
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Figure 11: Effect of PF-04886847 on activated factor XI (FXIa) in fluid phase. 2 nM FXIa
was incubated with 0.291 mM S2366 in the presence of increasing concentrations of PF04886847, PD-0180988, Kallistop or SBTI for 1 hr at 37ºC. The liberation of paranitroaniline
from S2366 was measured as the change in absorbance at 405 nm. Data are expressed as mean ±
SEM (n = 9). ** P < 0.01, *** P < 0.001 versus PD-0180988.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Like PK, FXI also circulates in the plasma bound to HK (Bouma et al., 1983). The HKFXI complex consisting of two molecules of HK and one molecule of FXI assembles on
endothelial cells by a mechanism similar to that of the HK-PK complex (Shariat-Madar et al.,
2001). HPAEC were sequentially incubated with increasing concentrations of HK and FXI (in a
2:1 ratio). Using the FXIa-specific chromogenic substrate S2366, it was observed that the
assembly of HK-FXI complex on HPAEC led to dose-dependent activation of FXI to FXIa.
However, in a parallel experiment, FXI activation was not observed on HK-pretreated microtiter
plate, suggesting that the activation of FXI was endothelial-cell dependent and not due to its
autoactivation (Figure 12A). Further, using confocal microscopy, it was shown that the assembly
of HK-FXI complex on HPAEC led to an increase in intracellular Ca2+ levels, thus confirming
FXI activation on endothelial cells (Figure 12A Inset). The HK-FXI activation assay was used to
study the effect of PF-04886847, PD-0180988, Kallistop and SBTI on FXIa activity on HPAEC.
Whereas, PF-04886847 and SBTI blocked FXIa activity with ki values of 1.1 µM and 1.2 µM,
respectively, Kallistop and PD-0180988 had no effect (Figure 12B).
Next, to further establish the selectivity profile of PF-04886847, experiments were
performed to examine the effect of this compound on FXIIa, FIXa, FXa, TF/FVIIa complex,
thrombin, tissue plasminogen activator (tPA), plasmin, trypsin and activated protein C (APC).
The activity of FXIIa was unaffected by PF-04886847 at concentrations ranging from 0.3 – 300
µM (Figure 13). PF-04886847 was 100-500 fold more selective for kallikrein than FIXa, FXa,
trypsin, APC and tPA (Table 4). Surprisingly, PF-04886847 showed strong inhibitory activity
against TF/FVIIa complex, thrombin and plasmin in the nanomolar range. Nevertheless, PF04886847 was still 5-25 fold more selective for kallikrein than TF/FVIIa, thrombin and plasmin
(Table 4).
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Figure 12: Effect of PF-04886847 on FXIa activity on HPAEC. Panel A. Activation of FXI
on HPAEC. HPAEC were incubated with increasing concentrations of HK followed by FXI (2:1
ratio) for 1 hr each at 37ºC. Cells were then treated with 0.5 mM S2366 to measure the activity
of FXIa produced. In a parallel experiment, increasing concentrations of HK and FXI were
incubated in a microtiter plate to rule out FXI autoactivation. Inset shows increase in intracellular
Ca2+ in HPAEC in response to HK-FXI complex, suggesting FXI activation. Panel B. Inhibition
of FXIa by PF-04886847 on endothelial cells. HPAEC were treated with 80 nM HK and
incubated for 1 hr at 37ºC. Cells were then incubated with 40 nM FXI in the presence of
increasing concentrations of PF-04886847, PD-0180988, Kallistop or SBTI for 1 hr at 37ºC.
FXIa activity was determined by addition of 0.5 mM S2366. Data are expressed as mean ± SEM
(n = 9). *** P < 0.001 versus PD-0180988.
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Figure 13: Effect of PF-04886847 on activated factor XII (FXIIa). 20 nM FXIIa was
incubated with 0.5 mM S2302 in the presence of increasing concentrations of PF-04886847, PD0180988, Kallistop or SBTI for 1 hr at 37ºC. The liberation of paranitroanilide from S2302 was
measured as the change in absorbance at 405 nm. Data are expressed as mean ± SEM (n = 9).
[Reprinted with copyright permission from Kolte et al. (2011)]

D. PF-04886847 inhibits plasma kallikrein-dependent BK production and subsequent B2
receptor signaling pathway in endothelial cells –
Plasma kallikrein cleaves HK to liberate the potent pro-inflammatory peptide BK. BK
upon activation of its constitutive B2 receptors on endothelial cells leads to an increase in
intracellular Ca2+ level and subsequent production of nitric oxide (NO) and prostacyclin (PGI2),
ultimately leading to vasodilation, increased vascular permeability and edema. Since PF04886847 effectively inhibited kallikrein activity on endothelial cells, we studied the ability of
this compound to block kallikrein-dependent BK production and B2 receptor-mediated
intracellular processes. PF-04886847 significantly inhibited HK-PK-induced BK production on
HPAEC [F(3,8) = 132.5, P < 0.0001, one-way ANOVA with Dunnett’s post hoc test], whereas
PD-0180988 (negative control) was ineffective (Figure 14). Further, using dual-excitation Ca2+
imaging, it was shown that the complex of HK-PK (300 nM each) induced a rapid transient
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increase in intracellular Ca2+ ([Ca2+]i), which was similar to that produced by BK (300 nM)
alone. PF-04886847 significantly blocked HK-PK-induced rise in [Ca2+]i in HPAEC [F(3,46) =
20.33, P < 0.0001, one-way ANOVA with Newman-Keul’s post hoc test] (Figure 15). The effect
of PF-04886847 on HK-PK-induced rise in [Ca2+]i was comparable to the inhibitory effect of
HOE140 on BK-evoked [Ca2+]i increase.

Table 4: Selectivity profile of PF-04886847

Serine Protease

ki (µM)

Fold Selectivity For
Kallikrein

Kallikrein

0.009 ± 0.003

1

FXIIa

N/A*

N/A

FXIa

1.0 ± 0.6

>100

FIXa

4.5 ± 1.2

>500

FXa

2.25 ± 1.9

>250

Trypsin

1.25 ± 0.5

>100

APC

1.07 ± 0.9

>100

tPA

5.09 ± 1.8

>500

TF/FVIIa

0.06 ± 0.04

>5

Thrombin

0.12 ± 0.03

>10

Plasmin

0.24 ± 0.04

>25

FXIIa: activated factor XII, FXIa: activated factor XI, FIXa: activated factor IX, FXa: activated
factor X, APC: activated protein C, tPA: tissue plasminogen activator, TF: tissue factor, FVIIa:
activated factor VII.Data are expressed as mean ± SEM (n = 3).
*No IC50/ki could be established because PF-04886847 (0.3-300 µM) did not block FXIIa
[Reprinted with copyright permission from Kolte et al. (2011)]
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Figure 14: Inhibition of kallikrein-dependent BK production in HPAEC by PF-04886847.
HPAEC were incubated with 100 nM HK for 1 hr at 37oC. At the end of incubation, cells were
washed and treated with 100 nM PK in the absence or presence of 10 µM PF-04886847 or PD0180988 (negative control) together with 1 µM lisinopril [angiotensin converting enzyme (ACE)
inhibitor] and 1 µM HOE140 (B2 receptor antagonist). After 1 hr incubation at 37ºC supernatants
from each well were collected and either frozen at -70 oC or immediately deproteinized with
trichloroacetic acid. BK level in the samples was determined using a commercial kit (MARKIT
BK). Data are expressed as mean ± SEM (n = 3). *** P < 0.001 versus HK+PK.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Figure 15: Effect of PF-04886847 on HK-PK-induced increase in intracellular Ca2+ level in
HPAEC. Monolayers of HPAEC seeded on cover slips were loaded with the ratiometric
fluorescence Ca2+ dye Fura-2 AM (10 µM) for 30 minutes at 37ºC. Cells were then washed,
mounted on a perfusion chamber and were continuously perfused with HEPES buffer at a rate of
1 mL/min. Cells were then treated with 300 nM HK after which 300 nM PK was injected in the
perfusion line in the absence or presence of 10 µM PF-04886847. HPAEC treated with 300 nM
BK in the absence or presence of 1 µM HOE140, a B2 receptor antagonist, served as control.
Changes in [Ca2+]i levels were measured as changes in the fluorescence ratio at 340/380
excitation wavelength using a dual excitation digital Ca2+ imaging system. Data are expressed as
mean ± SEM (n = 10-15). *** P < 0.001
[Reprinted with copyright permission from Kolte et al. (2011)]
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Next, the effect of PF-04886847 on HK-PK-induced NO production was determined
by measuring the amount of nitrate + nitrite, the metabolic end products of NO. Our initial
time course analysis showed that HK-PK (300 nM each) caused a rapid increase in NO
production in HPAEC, with the highest levels detected within 5 minutes. Therefore, this
time-point became the standard in subsequent experiments. 30 µM PF-04886847 blocked
HK-PK-induced NO production by 100% [F(2,6) = 13.06, P < 0.01, one-way ANOVA with
Dunnett’s post hoc test], suggesting complete inhibition of kallikrein and kallikreindependent BK production (Figure 16). Similarly, the effect of PF-04886847 on HK-PKinduced 6-keto PGF1α (a stable metabolite of PGI2) production was studied using a
colorimetric assay. Consistent with its effect on NO generation, 30 µM PF-04886847
significantly blocked 6-keto PGF1α production in HPAEC treated with HK-PK (300 nM
each) [F(2,9) = 15.66, P < 0.01, one-way ANOVA with Dunnett’s post hoc test] (Figure 17).

E. PF-04886847 inhibits HK-PK-mediated increase in endothelial monolayer permeability
and relaxation of lipopolysaccharide (LPS)-treated rat aortic rings –
Since NO and PGI2 mediate the pro-inflammatory effects of BK such as vasodilation and
increased vascular permeability, we hypothesized that PF-04886847 could serve as a potent antiinflammatory agent. Therefore, we evaluated the influence of PF-04886847 on endothelial
permeability using an in-vitro assay and on vascular contractility using an in-situ rat aortic ring
model.
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Figure 16: Inhibition of HK-PK-induced endothelial NO production by PF-04886847.
HPAEC cultured overnight in a 96-well microtiter plate were treated with 300 nM HK and
incubated for 1 hr at 37ºC. Cells were then washed and incubated with 300 nM PK in the absence
or presence of 30 µM PF-04886847 for 5 minutes at 37ºC. Supernatant from each well was
collected to measure the amount of nitrate + nitrite, the final products of NO metabolism, using a
commercially available fluorometric assay kit. Data are expressed as mean ± SEM (n = 3). ** P
< 0.01 versus HK+PK.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Figure 17: Inhibition of HK-PK-induced endothelial PGI2 production by PF-04886847.
HPAEC cultured overnight in a 96-well microtiter plate were treated with 300 nM HK and
incubated for 1 hr at 37ºC. Cells were then washed and incubated with 300 nM PK in the absence
or presence of 30 µM PF-04886847 for 1 hour at 37ºC. Supernatant from each well was collected
to measure the amount of 6-keto-PGF1α, a stable metabolite of PGI2, using a commercially
available colorimetric assay kit. Data are expressed as mean ± SEM (n = 3-6). ** P < 0.01 versus
HK+PK.
[Reprinted with copyright permission from Kolte et al. (2011)]
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The endothelial cell lining of the blood vessels constitutes a semi-permeable barrier
between the blood and the interstitial spaces of the body. This barrier is composed of
intracellular adherent, tight and gap junctions, including desmosomes (Bazzoni and Dejana,
2004). Endothelial cell monolayers cultured on semi-permeable membranes have been shown to
form adherent and tight junctions (Esser et al., 1998). This property of endothelial cells was used
to study the effect of PF-04886847 on HK-PK-induced increase in cell monolayer permeability.
HPAEC were seeded onto collagen-coated inserts having a semi-permeable membrane at the
bottom. After cell monolayer was formed, HPAEC were treated with cell basal medium
(negative control), 1 µg/ml LPS (positive control) or HK-PK (300 nM each) in the absence or
presence of PF-04886847 (30 µM) for 18 hours. The effect of PF-04886847 on HK-PK-induced
endothelial monolayer permeability was determined by measuring the passage of FITC-labeled
dextran across the endothelial cell-collagen-semi-permeable membrane barrier. As expected, 30
µM PF-04886847 completely inhibited HK-PK-induced increase in HPAEC monolayer
permeability [F(3,5) = 12.69, P < 0.01, one-way ANOVA with Dunnett’s post hoc test] (Figure
18).
Previous studies in our lab have shown that treatment of endothelial cells with
lipopolysaccharide (LPS) induces up-regulation of PRCP mRNA as well as PRCP-dependent
kallikrein and BK production (Ngo et al., 2009). Moreover, LPS-treated endothelial cells exhibit
a pro-inflammatory and pro-coagulant phenotype as evidenced by an increase in B1 receptor,
intercellular adhesion molecule-1 (ICAM-1), von Willebrand factor (vWF) and plasminogen
activator inhibitor-1 (PAI-1) mRNA expression. Since PF-04886847 completely inhibited HKPK-induced NO and PGI2 production in cultured endothelial cells, we examined the effect of this
compound on HK-PK-mediated relaxation of LPS-treated isolated rat aorta, as an in situ model
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of inflammation. The HK-PK complex relaxed non-LPS-treated (control) aortic rings in a dosedependent manner. The relaxation was greatly augmented in LPS-treated aorta, as evidenced by
a 70% reduction in the aortic ring tension in response to 100 nM HK-PK. PF-04886847
significantly attenuated the enhanced relaxation of LPS-treated aorta in response to HK-PK
[F(2,24) = 21.08, P < 0.0001 at 100 nM HK-PK, one-way ANOVA with Dunnett’s post hoc
test], providing further evidence for the anti-inflammatory potential of this compound (Figure
19).

F. Effects of PF-04886847 in a rat model of LPS-induced sepsis, ARDS and DIC –
Since PF-04886847 showed promising anti-inflammatory potential in in vitro and in situ
studies, investigations were performed to determine whether this novel kallikrein inhibitor is
protective in vivo in a rat model of LPS-induced sepsis and ARDS. Because PF-04886847 is a
novel compound, we first examined the effects of this kallikrein inhibitor on hematological and
metabolic parameters in rats. WBC, RBC and metabolic parameters in rats treated with PF04886847 (1 mg/kg) alone were similar to those in control animals (Tables 5, 6 and 7),
suggesting that at the dose used, the compound had no systemic or organ-specific adverse
effects. Since DMSO was used as a vehicle to dissolve PF-04886847, the effect of DMSO on
hematological and metabolic parameters was also determined. Treatment of rats with 0.2 ml of
99.7% DMSO caused a significant decrease in the total WBC count (P < 0.001 versus control)
(Table 5). This was primarily due to a dramatic reduction in the absolute lymphocyte count (P <
0.001 versus control) as a result of cytocidal effect of DMSO on lymphocytes, as previously
described (Schrek et al., 1967; Nash et al., 1983). Further, DMSO also caused a significant
decrease in the RBC count (P < 0.05) as compared to the control group (Table 6). The decrease
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Figure 18: Effect of PF-04886847 on HK-PK-mediated increase in HPAEC monolayer
permeability. HPAEC were cultured in collagen coated inserts having a semi-permeable
membrane at the bottom. After a monolayer was formed, the inserts were then treated with cell
basal medium (negative control), 1 µg/ml LPS (positive control) or HK-PK (300 nM each) in the
absence or presence of 30 µM PF-04886487 and incubated at 37ºC for 18 hrs. At the end of
incubation, the solution from each insert was removed and the inserts transferred to a
permeability detection plate. 500 µl of cell basal medium was added to each plate well and 150
µl of 1:20 FITC-Dextran was added to each insert. After 5 minutes of incubation at room
temperature the reaction was stopped by removing the inserts from the wells. The effect on
HPAEC monolayer permeability was quantified by measuring the fluorescence of the plate well
solution at an excitation wavelength of 485 nm and an emission wavelength of 528 nm using
BioTek Synergy 2 Multi-Mode Microplate Reader.
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Figure 19: Effect of PF-04886847 on HK-PK-induced relaxation of LPS-treated isolated rat
aorta precontracted by phenylephrine (PE). Rats were treated with LPS (1 mg/kg) to induce
inflammation. Part of the thoracic aorta was rapidly harvested and dissected into 2-3 mm
segments without branches. The aortic rings were then mounted on a Radnoti Tissue Bath
System and allowed to equilibrate with LPS (1 µg/ml) in the absence or presence of PF04886847 (20 µM) for 2 hrs while changing the chamber solution at 15 minutes intervals. After
resting tension of each aortic ring was stabilized, a sustained and stable contraction of 1.5 g was
maintained by adding 10 µM phenylepherine (PE). The anti-inflammatory property of PF04886847 was determined by measuring the change in aortic ring tension in response to
increasing concentrations (0 – 100 nM) of the HK-PK complex. + Statistically significant
difference versus LPS.
[Reprinted with copyright permission from Kolte et al. (2011)]
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Control

PF04886847

DMSO

DMSO
+LPS

PF-04886847
+LPS

Indomethacin
+LPS

WBC (x103/µl)

6.86 ± 0.38

7.15 ± 0.07

4.22 ± 0.29†

5.53 ± 0.32†

3.1 ± 0.31†*

2.22 ± 0.35†*

Lymphocytes (x103/µl)

4.77 ± 0.31

4.90 ± 0.22

2.41 ± 0.12†

2.54 ± 0.08†

1.65 ± 0.13†*

1.42 ± 0.26†*

Monocytes (x103/µl)

0.44 ± 0.09

0.34 ± 0.10

0.30 ± 0.08

0.24 ± 0.04

0.17 ± 0.03

0.14 ± 0.02

Granulocytes (x103/µl)

1.66 ± 0.12

1.92 ± 0.11

1.51 ± 0.24

2.60 ± 0.33†

1.29 ± 0.24*

0.66 ± 0.1†*

Lymphocytes (%)

69.4 ± 31.59

68.47 ± 2.84

52.27 ± 2.19

46.50 ± 2.98†

54.87 ± 4.26†*

63.5 ± 1.9*

Monocytes (%)

6.49 ± 1.32

4.73 ± 1.30

7.33 ± 2.35

4.65 ± 1.10

5.63 ± 0.99

6.77 ± 1.39

Granulocytes (%)

24.09 ± 0.93

26.80 ± 1.57

35.4 ± 3.18

48.88 ± 3.44†

39.5 ± 4.43†*

29.7 ± 1.61*

Total and differential WBC count was performed using VetScan HM2 (Abaxis) on blood samples collected from control (n = 8)
and PF-04886847 (1 mg/kg) (n = 3), DMSO (n = 3), DMSO + LPS (n = 5), PF-04886847 (1 mg/kg) + LPS (n = 6) and
Indomethacin (1 mg/kg) + LPS (n = 3) treated rats. Data are expressed as mean ± SEM. † P < 0.05 versus control, * P < 0.05
versus DMSO+LPS.
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Table 5: Effect of PF-04886847 on total and differential WBC count 6 hrs after LPS administration in rats

Control

PF-04886847

DMSO

DMSO
+LPS

PF-04886847
+LPS

Indomethacin
+LPS

RBC (x106/µl)

7.80 ± 0.16

8.14 ± 0.15

6.99 ± 0.31†

8.16 ± 0.28

8.10 ± 0.15

8.64 ± 0.09

Hemoglobin (g/dl)

14.31 ± 0.33

15.18 ± 0.22

13.4 ± 0.46

15.31 ± 0.58

15.03 ± 0.25

16.27 ± 0.17†

Hematocrit (%)

42.47 ± 0.96

44.77 ± 1.23

38.94 ± 0.94

44.39 ± 1.86

44.0 ± 10.96

46.22 ± 0.53

MCV (fl)

54.44 ± 0.69

54.75 ± 1.09

56.00 ± 1.53

54.5 ± 1.24

54.00 ± 0.54

53.67 ± 0.33

MCH (pg)

18.37 ± 0.17

18.68 ± 0.20

19.17 ± 0.20

18.81 ± 0.41

18.56 ± 0.21

18.8 ± 0.0

MCHC (g/dl)

33.71 ± 0.24

33.95 ± 0.48

34.33 ± 0.58

34.54 ± 0.48

34.31 ± 0.16

35.17 ± 0.07

RDWc (%)

15.82 ± 0.14

15.35 ± 0.06

15.83 ± 0.03

15.89 ± 0.17

15.59 ± 0.16

15.40 ± 0.12

RBC parameters were determined using VetScan HM2 (Abaxis) in blood samples collected from control (n = 8) and PF04886847 (1 mg/kg) (n = 3), DMSO (n = 3), DMSO + LPS (n = 5), PF-04886847 (1 mg/kg) + LPS (n = 6) and Indomethacin (1
mg/kg) + LPS (n = 3) treated rats. Data are expressed as mean ± SEM. † P < 0.05 versus control, * P < 0.05 versus DMSO+LPS.

62

Table 6: Effect of PF-04886847 on RBC parameters 6 hrs after LPS administration in rats

Table 7: Effect of PF-04886847 on clinical chemistry 6 hrs after LPS administration in rats
Indomethacin

+LPS

PF-04886847
+LPS

4.6 ± 0.2†

3.7 ± 0.1

3.5 ± 0.1†

3.7 ± 0.1

252.0 ± 21.6

279 ± 0.8

303.8 ± 23.2

280.2 ± 15.6

251.3 ± 28.6

52.6 ± 3.3

61.0 ± 2.5

54.5 ± 0.4

165.3 ± 28.7†

176.0 ± 12.1†

396.0 ± 34.3†*

779.7 ± 20.3

815.0 ± 11.9

829.7 ± 41.3

924.4 ± 24.8†

Total Bilirubin (mg/dl)

0.2 ± 0.01

0.2 ± 0.0

0.2 ± 0.0

0.3 ± 0.03†

0.4 ± 0.03†*

0.5 ± 0.08†*

BUN (mg/dl)

18.2 ± 1.4

20.0 ± 0.4

17.7 ± 2.0

51.4 ± 2.2†

54.5 ± 2.0†

49.3 ± 0.3†

Calcium (mg/dl)

11.4 ± 0.2

11.2 ± 0.2

11.7 ± 0.2

10.1 ± 0.3†

9.2 ± 0.2†*

9.2 ± 0.1†*

Phosphate (mg/dl)

9.3 ± 0.5

8.3 ± 0.8

10.7 ± 0.3

12.3 ± 0.5†

12.3 ± 0.7†

13.2 ± 0.7†

Creatinine (mg/dl)

0.3 ± 0.04

0.4 ± 0.10

0.2 ± 0.0

0.8 ± 0.08†

0.8 ± 0.06†

0.6 ± 0.09†

Glucose (mg/dl)

156.8 ± 5.4

151.5 ± 3.4

151.3 ± 7.9

104.1 ± 9.7†

108.3 ± 6.0†

99.7 ± 9.2†

Na+ (mmol/L)

140.4 ± 0.8

140.8 ± 0.8

145.0 ± 0.6

141.6 ± 0.7

140.8 ± 0.6

141.0 ± 1.0

K+ (mmol/L)

6.0 ± 0.4

5.3 ± 0.4

5.6 ± 0.3

5.5 ± 0.4

5.6 ± 0.2

5.9 ± 0.3

Total Protein (g/dl)

5.7 ± 0.1

6.0 ± 0.1

5.8 ± 0.1

5.2 ± 0.1†

4.9 ± 0.1†*

5.5 ± 0.1

Globulin (g/dl)

1.6 ± 0.1

1.8 ± 0.1

1.2 ± 0.1

1.5 ± 0.1

1.5 ± 0.04

1.8 ± 0.1

PF-04886847

DMSO

4.0 ± 0.1

4.2 ± 0.1

ALP (U/L)

294.8 ± 22.1

ALT (U/L)

Albumin (g/dl)

Amylase (U/L)

DMSO

+LPS

1111.6 ± 25.8†* 1119.0 ± 48.2†*

Comprehensive metabolic panel was obtained using VetScan VS2 (Abaxis) on blood samples collected from control (n = 8) and
PF-04886847 (1 mg/kg) (n = 3), DMSO (n = 3), DMSO + LPS (n = 8), PF-04886847 (1 mg/kg) + LPS (n = 8) and Indomethacin
(1 mg/kg) + LPS (n = 3) treated rats. Data are expressed as mean ± SEM. † P < 0.05 versus control, * P < 0.05 versus DMSO+LPS

63

Control

in RBC count could be explained by the ability of DMSO to cause intravascular hemolysis, as
previously described (DiStefano and Klahn, 1965; Norred et al., 1970). Regardless of its
influence on WBC and RBC counts, DMSO had no effect on metabolic parameters, suggesting
lack of hepatic or renal toxicity at the concentration used (Table 7).
Next, we investigated the anti-inflammatory effect of PF-04886847 in a rat model of
LPS-induced sepsis and ARDS. Sepsis was induced in male Sprague-Dawley rats using
intravenous LPS (10 mg/kg). In addition to i.v. administration, intranasal instillation of LPS (20
µg) was used to augment the acute lung injury. Six hours after endotoxin administration, animals
in the DMSO+LPS group developed severe sepsis with multiple organ dysfunction syndrome as
evidenced by decreased rectal temperature (34.2 ± 0.6 versus 37.0 ± 0.1ºC in control); decreased
lymphocyte and increased granulocyte counts; elevated serum ALT, amylase, total bilirubin,
BUN, creatinine and phosphate; and reduced glucose and calcium levels, as compared to the
control group (P < 0.05) (Tables 5, 6 and 7). Of note, since DMSO alone also caused a
significant reduction in the lymphocyte count, the decreased lymphocyte count in DMSO+LPS
treated rats could be attributed to DMSO, LPS or both.
PF-04886847 (1 mg/kg) administered i.v. 30 minutes prior to LPS protected rats against
some of the adverse effects of endotoxin. Pre-treatment with PF-04886847 prevented LPSinduced increase in granulocyte count in the systemic circulation [F(5,22) = 7.616, P < 0.001,
one-way ANOVA with Newman-Keul’s post hoc test] (Table 5). Interestingly, compared to
DMSO+LPS, animals treated with PF-04886847+LPS showed a greater reduction in lymphocyte
(~35% reduction, P < 0.05) and monocyte (~29% reduction, P > 0.05) counts. LPS stimulates
monocytes/macrophages, lymphocytes and endothelial cells to release the potent proinflammatory cytokine, TNF-α (Brunialti et al., 2006). Since TNF-α is known to induce
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peripheral neutrophilia, we hypothesized that the reduction in LPS-mediated increase in
granulocyte count caused by PF-04886847 could be due to inhibition of TNF-α release (Ulich et
al., 1989). However, PF-04886847 had no effect on LPS-induced increase in plasma TNF-α level
(Figure 20).
Since NSAIDs are potent anti-inflammatory agents and are known to decrease neutrophil
count and induce neutropenia, we compared the effect of PF-04886847 on granulocyte count
with that of Indomethacin, a non-selective cyclooxygenase (COX) inhibitor (Strom et al., 1993).
Indomethacin (1 mg/kg) administered i.v. 30 minutes prior to LPS produced a similar effect on
lymphocyte, monocyte and granulocyte counts as PF-04886847 (Table 6). Further, both PF04886847 and Indomethacin significantly decreased plasma 6-keto PGF1α (a stable metabolite of
PGI2) levels in LPS treated rats (P < 0.05 and P < 0.001 versus DMSO+LPS, respectively)
(Figure 21). Since PGI2 is a potent vasodilator and inhibitor of leukocyte adhesion, we propose
that the effect of PF-04886847 and Indomethacin on differential WBC count could be related, at
least in part, to the ability of these agents to modulate vascular permeability, leukocyteendothelial cell adhesion and leukocyte transmigration during sepsis (Jones and Hurley, 1984;
Bath et al., 1991; Lindemann et al., 2003).
Neither PF-04886847 nor Indomethacin attenuated the LPS-induced increase in ALT,
total bilirubin, BUN and creatinine, indicating that a single i.v. dose of these agents was
ineffective in protecting the animals against LPS-mediated acute hepatic and renal injury (Table
7). Conversely, serum ALT and total bilirubin levels were significantly higher in
Indomethacin+LPS group as compared to DMSO+LPS group (P < 0.001 and P < 0.01,
respectively). This could be due to NSAID-induced hepatocellular injury as previously described
(Lacroix et al., 2004; Lapeyre-Mestre et al., 2006; Dial et al., 2008).
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Figure 20: Effect of PF-04886847 on plasma TNF-α levels 6 hrs after LPS administration in
rats. TNF-α levels were measured in plasma samples collected 6 hrs after LPS administration
from control (n = 5) and PF-04886847 (1 mg/kg) (n = 3), DMSO + LPS (n = 5) and PF04886847 (1 mg/kg) + LPS (n = 5) treated rats using ELISA. Data are expressed as mean ±
SEM. ### P < 0.001 versus control.
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Figure 21: Effect of PF-04886847 on plasma 6-keto PGF1α levels 6 hrs after LPS
administration in rats. 6-keto PGF1α levels were measured in plasma samples collected 6 hrs
after LPS administration from control (n = 4) and PF-04886847 (1 mg/kg) (n = 3), DMSO + LPS
(n = 4), PF-04886847 (1 mg/kg) + LPS (n = 5) and Indomethacin (1 mg/kg) + LPS (n = 3)
treated rats using ELISA. Data are expressed as mean ± SEM. ### P < 0.001 versus control, * P <
0.05 and *** P < 0.001 versus DMSO+LPS.

67

BAL fluid total leukocyte count (BALF TLC) was determined to assess the extent of lung
inflammation. Rats in the DMSO+LPS group showed a significant (P < 0.001) increase in the
BALF TLC as compared to those in the control group (Figure 22), suggestive of intra-alveolar
inflammatory cell infiltration, one of the pathological hallmarks of ARDS. BALF TLC was
significantly decreased in rats pre-treated with PF-04886847 [F(4,13) = 18.66, P < 0.05, one-way
ANOVA with Newman-Keul’s post hoc test], suggesting that the kallikrein inhibitor reduced
LPS-induced intra-alveolar inflammatory cell infiltration (Figure 22). On the other hand, BALF
TLC was only modestly reduced in Indomethacin+LPS group and this effect was not statistically
significant.
Sepsis is the leading cause of disseminated intravascular coagulation (DIC). Intravenous
administration of LPS is the most commonly used technique to model DIC in laboratory animals
(Berthelsen et al., 2011). In the rat model used in this study, i.v. administration of LPS (10
mg/kg) elicited all pathological features of DIC including reduced platelet count (Table 8),
prolonged bleeding time (BT) (Table 9), decreased plasma fibrinogen levels (Figure 23A) and
increased plasma D-dimer levels (Figure 23B) (P < 0.05 versus control). Since PF-04886847
showed strong inhibitory potency towards plasma kallikrein, TF/FVIIa and thrombin in in vitro
studies, we hypothesized that the combined inhibition of the intrinsic and extrinsic pathways of
the coagulation system by PF-04886847 could have a beneficial effect in LPS-induced DIC.
However, contrary to our hypothesis, at the dose (1 mg/kg) used in this study, PF-04886847
administered as a single i.v. injection 30 minutes prior to LPS did not attenuate endotoxininduced decrease in platelet count and plasma fibrinogen levels as well as increase in plasma Ddimer levels (Table 9, Figure 23).
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Figure 22: Effect of PF-04886847 on BAL total leukocyte count 6 hrs after LPS
administration in rats. BAL was performed 6 hours after LPS administration (20 µg i.n. + 10
mg/kg i.v.). Total number of leukocytes (cells between 8 – 20 µm) were counted in the BAL
fluid obtained from control (n = 4) and PF-04886847 (1 mg/kg) (n = 3), DMSO (n = 3), DMSO
+ LPS (n = 4), PF-04886847 (1 mg/kg) + LPS (n = 4) and Indomethacin (1 mg/kg) + LPS (n = 3)
treated rats using Coulter counter. Data are expressed as mean ± SEM. ## P < 0.01 and ### P <
0.001 versus control, * P < 0.05 versus DMSO+LPS.
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DMSO

PF-04886847

Indomethacin

+LPS

+LPS

+LPS

717.5 ± 49.4†

199.67 ± 18.29†

81.60 ± 6.03†*

48 ± 12.9†*

0.44 ± 0.02†

0.49 ± 0.04†

0.13 ± 0.01†

0.05 ± 0.01†*

0.03 ± 0.01†*

6.99 ± 0.13

6.55 ± 0.07

6.8 ± 0.15

6.70 ± 0.24

6.44 ± 0.06

6.53 ± 0.15

32.73 ± 0.24

32.05 ± 0.25

32.2 ± 0.46

32.12 ± 1.02

31.1 ± 0.44

33.67 ± 1.3

Control

PF-04886847

DMSO

Platelets (x103/µl)

852 ± 26.09

678.5 ± 34.77†

Plateletcrit (%)

0.60 ± 0.01

MPV (fl)
PDWc (%)

Platelet parameters were determined using VetScan HM2 (Abaxis) in blood samples collected from control (n = 8) and PF04886847 (1 mg/kg) (n = 3), DMSO (n = 3), DMSO + LPS (n = 5), PF-04886847 (1 mg/kg) + LPS (n = 6) and Indomethacin (1
mg/kg) + LPS (n = 3) treated rats. Data are expressed as mean ± SEM. † P < 0.05 versus control, * P < 0.05 versus DMSO+LPS.

Table 9: Effect of PF-04886847 on tail bleeding time in LPS-treated rats

Bleeding Time (s)

Control

PF-04886847

DMSO

290.7 ± 48.3

570 ± 30.0†

342.5 ± 22.5

DMSO

PF-04886847

Indomethacin

+LPS

+LPS

+LPS

600 ± 0.0†

600 ± 0.0†

600 ± 0.0†

Bleeding time was determined in control (n = 6) and PF-04886847 (1 mg/kg) (n = 4), DMSO (n = 3), DMSO + LPS (n = 9), PF04886847 (1 mg/kg) + LPS (n = 9) and Indomethacin (1 mg/kg) + LPS (n = 3) treated rats using the tail tip transaction
technique as described under ‘experimental methods.’ Data are expressed as mean ± SEM. † P < 0.05 versus control.
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Table 8: Effect of PF-04886847 on platelet count 6 hrs after LPS administration in rats
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Figure 23: Effect of PF-04886847 on plasma fibrinogen and D-dimer levels 6 hrs after LPS
administration in rats. Plasma fibrinogen (Panel A) and D-dimer (Panel B) levels were
measured in plasma collected from control (n = 5) and PF-04886847 (1 mg/kg) (n = 4), DMSO +
LPS (n = 5) or PF-04886847 (1 mg/kg) + LPS (n = 7) treated rats. Data are expressed as mean ±
SEM. ### P < 0.001 versus control.
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Surprisingly, PF-04886847 alone caused a significant decrease in the platelet count which
was also associated with prolongation of the BT (P < 0.001 versus control) (Tables 8, 9). Further,
animals treated with PF-04886847+LPS as well as Indomethacin+LPS showed a significantly (P
< 0.01) greater reduction in the platelet count as compared to DMSO+LPS treated animals
(Table 9). This could be due to thrombocytopenic effect of the drugs themselves. Alternatively,
since both PF-04886847 and Indomethacin caused a significant decrease in plasma PGI2 levels
(Figure 21), we speculate that the reduced platelet count could be due to increased platelet
adhesion and aggregation, especially in the pulmonary microvessels, during sepsis. However,
additional investigations would be needed to confirm this, which are out of scope of the present
study.
Taken together, in the rat model of LPS-induced sepsis used in this study, pretreatment
with PF-04886847 (1 mg/kg i.v.) prevented LPS-induced increase in granulocyte count in the
systemic circulation and reduced intra-alveolar leukocyte infiltration. However, a single i.v. dose
of PF-04886847 did not protect the animals against LPS-mediated acute hepatic and renal injury
and DIC.

G. Effects of PF-04886847 in a balloon-induced femoral artery injury model of thrombosis
in hypercholesterolemic rabbits –
The antithrombotic properties of PF-04886847 were further evaluated in a rabbit femoral
artery balloon injury model designed to mimic clinical conditions under which patients with
atherosclerosis develop thrombotic events secondary to acute plaque rupture. In this model, PF04886847 administered as an i.v. infusion during plaque rupture reduced thrombus mass in a
dose-dependent manner from 16 ± 2 mg (control) to 8 ± 3 mg (P < 0.05) and 2 ± 1 mg (P <
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0.001) at the doses of 0.3 mg/kg and 1 mg/kg, respectively (Table 5). Further, PF-04886847 at 1
mg/kg significantly prolonged both PT [F(3,19) = 42, P < 0.001, one-way ANOVA with
Dunnett’s post-hoc test] and aPTT [F(3,19) = 11.66, P < 0.001, one-way ANOVA with
Dunnett’s post-hoc test], suggesting that at this dose, the compound blocked both extrinsic and
intrinsic pathways of the coagulation system. Despite its effects on thrombus mass, PT and
aPTT, PF-04886847 had minimal effect on BT as determined using an ear bleeding time
technique (Table 10).

Table 10: Effect of PF-04886847 on thrombus mass, PT, aPTT and BT in a balloon-induced
femoral artery injury model of thrombosis in hypercholesterolemic rabbits
Treatment
Group
Control
PF-04886847

Dose
(mg/kg)

n

Thrombus
Mass (mg)

PT
(fold)

aPTT
(fold)

BT
(fold)

0

8

16 ± 2

1.0 ± 0.01

1.0 ± 0.1

1.1 ± 0.1

0.1

5

19 ± 2

1.0 ± 0.01

1.1 ± 0.1

1.1 ± 0.1

0.3

5

8 ± 3*

1.0 ± 0.02

1.3 ± 0.1

1.6 ± 0.7

1.0

5

2 ± 1*

1.2 ± 0.02*

1.8 ± 0.1*

1.3 ± 0.2

Rabbits were fed high cholesterol diet for 4 weeks and subjected to femoral artery endothelial
injury to induce formation of a localized atherosclerotic plaque. After 4 weeks, the plaque was
ruptured using a balloon angioplasty catheter to induce thrombus formation. Vehicle or PF04886847 (0.1, 0.3 or 1 mg/kg) was administered as an i.v. infusion in a total volume of 2 mL
over a 3-minute period starting halfway through the acute plaque rupture and ending at stasis.
After 15 minutes of stasis, the injured segment of the artery was removed and the thrombus was
extracted and weighed to determine the thrombus mass. Prothrombin time (PT), activated partial
thromboplastin time (aPTT) and bleeding time (BT) were determined at baseline and post-drug
infusion. Data are expressed as mean ± SEM. PT, aPTT and BT values are fold change compared
to the respective baseline. * P < 0.05 versus control.
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IV. DISCUSSION

Our investigations have helped characterize the pharmacodynamic properties of the novel
compound, PF-04886847. The major findings of this study are: (1) PF-04886847 is a potent and
selective small molecule inhibitor of plasma kallikrein; (2) PF-04886847 inhibited kallikreinmediated BK production and subsequent BK-dependent B2 receptor signaling pathways in
endothelial cells; (3) PF-04886847 abolished HK-PK-induced increase in endothelial monolayer
permeability as well as inhibited HK-PK-mediated relaxation of LPS-treated isolated rat aortic
rings; (4) in a rat model of LPS-induced sepsis and ARDS, PF-04886847 attenuated the LPSinduced increase in granulocyte count in the systemic circulation and total leukocyte count in the
bronchoalveolar lavage fluid; and (5) in a balloon-induced femoral artery injury model of
thrombosis in hypercholesterolemic rabbits, PF-04886847 reduced thrombus mass and prolonged
PT and aPTT.
Plasma kallikrein has two major pathophysiological functions. First, plasma kallikrein
cleaves HK to release BK (Kerbiriou and Griffin, 1979). BK and its metabolite des-Arg9-BK are
potent pro-inflammatory peptides that promote inflammation via activation of B2 and B1
receptors, respectively (Regoli et al., 1998). Second, kallikrein activates FXII to αFXIIa
(Cochrane and Griffin, 1979). αFXIIa in turn activates FXI to FXIa, thereby initiating a series of
proteolytic reactions (intrinsic pathway of coagulation) ultimately leading to the production of
thrombin, fibrin and clot formation. Plasma kallikrein, therefore, plays an important role in the
pathogenesis of inflammation and thrombosis and represents a valid target for the treatment of
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various pathological conditions such as HAE, post-CPB SIRS and sepsis (Bryant and ShariatMadar, 2009).
Whereas B2 receptors are constitutively expressed, the expression of B1 receptors is
induced during inflammation. Although inhibitors of the B2 receptor signaling pathway are being
used clinically in the treatment of HAE, this approach has been unsuccessful in the management
of post-CPB SIRS and sepsis, in which the inducible B1 receptors play a critical role in
potentiating the inflammatory response (2010; Feletou et al., 1996). Further, CPB and sepsis are
also associated with widespread activation of the coagulation system leading to thrombosis
and/or bleeding. Therefore, inhibition of plasma kallikrein could be a better approach in the
treatment of these conditions by simply reducing kallikrein-mediated BK production and FXII
activation. Thus, the primary objective of this study was to develop and characterize a novel,
potent small molecule inhibitor of plasma kallikrein and to evaluate its potential usefulness in the
treatment of kallikrein-mediated inflammatory and thrombotic disorders.
Using high-throughput screening of a library of 2.2 million compounds, PF-04886847
was identified as a novel small molecule (M.W. 589 Da) inhibitor of plasma kallikrein (Table 3).
PF-04886847 abolished the proteolytic activity of pure kallikrein with a Ki of 0.009 µM (Figure
2). Further, kinetic studies showed that PF-04886847 is a competitive inhibitor of plasma
kallikrein at a concentration ranging from 0.001 – 0.03 µM (Figure 3). PF-04886847 also
inhibited the activity of kallikrein produced as a result of the assembly of HK-PK complex on
endothelial cells with a Ki of 0.3 µM (Figure 4). Thus, our initial studies showed that PF04886847 is a novel, potent competitive small molecule inhibitor of plasma kallikrein.
PK, the proenzyme of kallikrein, circulates in the plasma as a complex with HK. The
assembly and activation of the HK-PK complex on endothelial cells is mediated via interaction
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of HK with a multiprotein cell membrane complex consisting of cytokeratin 1 (CK1), urokinase
plasminogen activator receptor (uPAR) and complement C1q receptor (gC1qR) (Joseph et al.,
1999; Mahdi et al., 2001). PK is then converted to kallikrein by the constitutively expressed
serine protease PRCP on endothelial cell surface (Shariat-Madar et al., 2002). Of note, other
cellular proteins such as heat shock protein 90 (Hsp90) have also been shown to convert PK to
kallikrein on endothelial cells (Joseph et al., 2002). Since PF-04886847 inhibited the activity of
kallikrein produced on endothelial cells, we determined whether PF-04886847 interferes with the
assembly and/or activation of the HK-PK complex on HPAEC. These experiments showed that
PF-04886847 did not block the binding of HK to endothelial cells or PK to HK (Figures 5, 6).
Further, the activity of rPRCP was also unaffected by PF-04886847 (Figure 7). These
observations confirmed that PF-04886847 selectively blocks the activity of kallikrein produced
via activation of the HK-PK complex on endothelial cells.
Plasma kallikrein is a serine protease consisting of a heavy chain and a light chain linked
via a single disulfide bond between Cys364 and Cys484. The N-terminal heavy chain of 371
amino acids (53 kDa) contains four apple domains (A1 – A4), the homologues of which are also
found in factor XI (FXI), whereas the C-terminal light chain of 248 amino acids (33-36 kDa)
forms the protease domain and contains the catalytic triad His415, Asp464 and Ser559 (McMullen et
al., 1991; van der et al., 1982). There is extensive sequence conservation between the protease
domain of plasma kallikrein and of other trypsin-like serine proteases (Tang et al., 2005).
Therefore, we determined the effect of PF-04886847 on other serine proteases of the kallikreinkinin, coagulation and fibrinolytic systems. Compared to kallikrein, PF-04886847 was less
effective in inhibiting other components of the plasma KKS, such as FXIa (>100 times less
selective) (Figure 8) and FXIIa (no inhibition at 0.3 – 300 µM) (Figure 10). PF-04886847 was
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100-500 fold more selective for kallikrein than FXa, trypsin, APC and tPA and 5-25 fold more
selective for kallikrein than TF/FVIIa, thrombin and plasmin (Table 2). Thus, PF-04886847 was
identified as a strong as well as a highly selective inhibitor of plasma kallikrein.
Plasma kallikrein cleaves HK to liberate the pro-inflammatory peptide BK. BK upon
activation of its constitutive B2 receptors on endothelial cells leads to an increase in intracellular
Ca2+ level and subsequent production of nitric oxide (NO) and prostacyclin (PGI2) (Hong, 1980;
Zhao et al., 2001). NO and PGI2 are potent vasodilators contributing to increased vascular
permeability and edema during inflammation and sepsis. Our in vitro studies using cultured
HPAEC showed that PF-04886847 is a potent inhibitor of kallikrein-mediated BK production as
well as subsequent BK-dependent B2 receptor-mediated increase in intracellular Ca2+ and NO
and PGI2 production in endothelial cells. Further, PF-04886847 completely abolished HK-PKinduced increase in endothelial monolayer permeability, suggesting that this novel kallikrein
inhibitor could be useful in preventing vascular leakage and edema formation during
inflammation through inhibition of kallikrein-dependent BK production.
The enhanced activation of plasma KKS during experimental and human sepsis has been
described (Oehmcke and Herwald, 2010). During endotoxemia, the activation of PK to plasma
kallikrein is potentiated resulting in robust generation of BK. BK-mediated B2 and B1 receptor
activation and subsequent NO and PGI2 production is responsible for hypotension and
hypotensive shock during sepsis (Katori et al., 1989; Shin et al., 1996). Previous studies in our
lab have shown that treatment of endothelial cells with lipopolysaccharide (LPS) induces upregulation of PRCP mRNA as well as PRCP-dependent kallikrein and BK production (Ngo et al.,
2009). Hence, we determined whether PF-04886847 is able to block the effect of kallikrein on
endotoxin-treated isolated rat aorta, an in situ model of inflammation. PF-04886847 blocked HK-
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PK-induced relaxation of LPS-treated isolated rat aorta, providing further evidence for the antiinflammatory potential of this compound.
Our next set of investigations was designed to characterize the anti-inflammatory
properties of PF-04886847 in vivo in a rat model of LPS-induced sepsis and ARDS. Although
there is no experimental model that mimics all pathological features of human sepsis and ARDS,
i.v. administration of LPS (endotoxin) is a widely accepted technique that has been used
successfully to model sepsis and ARDS in laboratory animals for preliminary testing of potential
therapeutic agents (Buras et al., 2005; Matute-Bello et al., 2008). Since lung injury following i.v.
LPS alone is associated with only mild intra-alveolar neutrophilic infiltrates, a combination of
intranasal (i.n.) and i.v. administration was used in this study to augment the lung injury (MatuteBello et al., 2008).
In the rat model of LPS-induced sepsis used in this study, PF-04886847 (1 mg/kg)
administered as a single i.v. dose 30 minutes prior to LPS prevented endotoxin-induced increase
in granulocyte count in the systemic circulation (Table 5). However, this effect did not translate
into prevention of LPS-induced acute hepatic and renal injury (Table 7). Next, we attempted to
determine the mechanism through which PF-04886847 might reduce the increase in granulocyte
count during sepsis. Early (< 1 hr) neutropenia and pulmonary and hepatic microvascular
sequestration of neutrophils are well documented during experimental sepsis (Haslett et al.,
1987; Zhang et al., 1994). Neutrophilia observed during the later stages of endotoxemia (3 – 8
hrs) might be due to the subpopulation of neutrophils newly released from the bone marrow
(Wagner and Roth, 1999). These immature neutrophils also have a propensity to sequester in
pulmonary microvessels (van Eeden et al., 1997). Thus, we hypothesized that the PF-04886847mediated reduction in granulocyte count in LPS treated rats could be due to: (1) inhibition of
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neutrophil release from the bone marrow, or (2) paradoxical increase in neutrophil adhesion
and/or microvascular sequestration.
LPS stimulates monocytes/macrophages, lymphocytes, neutrophils and endothelial cells
to release the potent pro-inflammatory cytokines, TNF-α and IL-1β (Brunialti et al., 2006).
During sepsis, TNF-α and IL-1β promote the release of immature neutrophils from the bone
marrow thus contributing to peripheral neutrophilia (Ulich et al., 1989; Ulich et al., 1987).
Further, Santos et al. have demonstrated that LPS-induced neutrophil migration involves BKdependent B2 receptor activation coupled to synthesis/release of TNF-α and IL-1β (Santos et al.,
2003). Furthermore, BK acting via the inducible B1 receptors has been shown to activate NF-κB
and stimulate the release of inflammatory cytokines such as TNF-α and IL-1β from macrophages
(Tiffany and Burch, 1989). Therefore, we examined whether the reduction in LPS-mediated
increase in granulocyte count caused by PF-04886847 is due to its ability to attenuate BKdependent cytokine production thereby influencing the release of immature neutrophils from the
bone marrow. Contrary to our assumption, PF-04886847 did not inhibit LPS-induced increase in
plasma TNF-α level (Figure 20), suggesting the existence of an alternative mechanism. However,
the effect of PF-04886847 on plasma IL-1β level as well as bone marrow granulocyte count
needs to be evaluated before completely rejecting this hypothesis.
BK, produced as a result of kallikrein-mediated cleavage of HK, stimulates endothelial
cells to release PGI2 via activation of B2 and/or B1 receptor signaling pathway (Orleans-Juste et
al., 1989). Indomethacin, a non-selective COX inhibitor, inhibits BK-mediated PGI2 production,
suggesting that this response is COX dependent (Brown et al., 1996). In the present study we
showed that PF-04886847 attenuated HK-PK-induced increase in PGI2 in HPAEC via inhibition
of kallikrein-dependent BK production (Figure 17). These data suggest that both PF-04886847
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and Indomethacin act via different mechanisms to regulate kallikrein or BK-mediated endothelial
PGI2 production. Further, since PGI2 is a potent inhibitor of leukocyte-endothelial cell adhesion
we compared the effect of PF-04886847 on granulocyte count with that of Indomethacin in the
rat model of LPS-induced sepsis (Jones and Hurley, 1984; Lindemann et al., 2003; Bath et al.,
1991). Indomethacin produced a similar, although more robust, effect as PF-04886847 on total
and differential WBC counts in LPS treated rats (Table 5). Further, as expected, both PF04886847 and Indomethacin significantly reduced the elevated plasma 6-keto PGF1α levels in
LPS treated rats (Figure 21). Therefore, we propose that the decrease in granulocyte count seen
with these agents could be due to a paradoxical increase in leukocyte adhesion to vessel walls,
especially in pulmonary and/or hepatic microvessels, as a result of reduced plasma PGI2 levels
(Jones and Hurley, 1984; Lindemann et al., 2003). However, histopathological examination of
the lungs and/or liver is needed to confirm or refute this possibility. Nonetheless, since an
increase in PGI2 is known to contribute to circulatory failure during endotoxemia, PF-04886847
could be useful in preventing hypotensive shock during sepsis via inhibition of LPS-induced
kallikrein-dependent increase in PGI2 production (Hocherl et al., 2008).
Sepsis is the leading cause of ARDS. Neutrophilic alveolitis, interstitial and intraalveolar
edema and development of microthrombi are the key pathological features of ARDS
(Tomashefski, Jr., 1990). The activation of plasma KKS in human and experimental ARDS has
been described (Schapira et al., 1985; Carvalho et al., 1988). In the animal model of sepsis used
in this study, PF-04886847 inhibited LPS-induced increased in bronchoalveolar lavage fluid total
leukocyte count (BALF TLC) (Figure 22). These data are consistent with recent observations by
Campanholle et al. that the B1 receptor antagonist R-954 prevents increase in cellular infiltration
and protein content in the BALF in LPS-treated mice (Campanholle et al., 2010). Moreover,
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plasma kallikrein is known to stimulate neutrophil chemotaxis, aggregation, oxidative
metabolism and elastase release (Kaplan et al., 1972; Schapira et al., 1982; Wachtfogel et al.,
1983). Since neutrophils are thought to play a central role in the pathogenesis of ARDS, our
findings suggest that the inhibition of plasma kallikrein and subsequent BK production by PF04886847 might be useful in preventing neutrophil-mediated acute lung injury during sepsis
(Grommes and Soehnlein, 2011).
Besides ARDS, DIC is another common complication of sepsis. Since PF-04886847
showed strong inhibitory potency towards plasma kallikrein, TF/FVIIa and thrombin in in vitro
studies, we hypothesized that the combined inhibition of the intrinsic (kallikrein) and extrinsic
(TF/FVIIa and thrombin) pathways of the coagulation system by PF-04886847 could have a
beneficial effect in LPS-induced DIC. However, contrary to our hypothesis, at the dose (1
mg/kg) used in this study, PF-04886847administered as a single i.v. injection 30 minutes prior to
LPS did not attenuate endotoxin-induced decrease in platelet count and plasma fibrinogen levels
as well as increase in plasma D-dimer levels. Previous studies have shown that the extrinsic
pathway of the coagulation system might be more important than the intrinsic pathway in the
development of DIC (Warr et al., 1990; de Pont et al., 2004). Uchiba et al. (1997) demonstrated
that the plasma kallikrein inhibitor PKSI-527 prevents lung inflammation but not DIC in
endotoxin treated rats. Further, Pixley et al. (1993) showed that the infusion of monoclonal
antibody against FXII prevents hemodynamic alterations but not DIC induced by E. coli infusion
in baboons. Our present report is consistent with these observations. Since PF-04886847 is 5
times less potent in inhibiting TF/FVIIa, the lack of protection against DIC could be due to poor
inhibition of the extrinsic pathway at the dose used in our study. It is possible that PF-04886847
might prevent LPS-induced DIC at a higher dose due to its ability to inhibit TF/FVIIa. However,
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since the extrinsic pathway is essential for hemostasis, TF/FVIIa inhibition at a higher dose
might entail an increased risk of bleeding. Indeed, under our experimental conditions, PF04886847 at 1 mg/kg i.v. alone caused a significant decrease in the platelet count and
prolongation of the BT, as determined using the tail tip transection technique (Tables 8, 9). The
prolonged BT could be due to a combination of reduced platelet count as well as anti-coagulant
effect of PF-04886847. Hence, in the present study, we did not use a higher dose of PF04886847. However, additional investigations are required to determine whether the use of PF04886847 at increasing doses is associated with an increased risk of bleeding and to establish the
risk: benefit ratio.
Further, in the rat model of LPS-induced sepsis, platelet count was lower in animals
treated with PF-04886847+LPS or Indomethacin+LPS as compared to DMSO+LPS treated
animals (Table 9). This could be due to several possibilities. First, the decreased platelet count
could be dut to thrombocytopenic effect of the drugs themselves. Second, since both PF04886847 and Indomethacin caused a significant decrease in plasma PGI2 levels (Figure 21), it is
conceivable to speculate that the reduced platelet count could be due to increased platelet
adhesion, especially in the pulmonary microvessels, during sepsis. Third, recent studies have
described the dependence of platelet recruitment in postcapillary venules on leukocyteendothelial adhesion and activation (Cooper et al., 2004; Li et al., 2000; Singer et al., 2006).
Hence, it can be proposed that the decreased platelet count seen in PF-04886847+LPS and
Indomethacin+LPS treated animals could be due to platelet recruitment in microvessels
secondary to increased leukocyte-endothelial adhesion as a result of reduced PGI2 levels.
Lastly, we evaluated the anti-thrombotic properties of PF-04886847 using a ballooninduced femoral artery injury model of thrombosis in hypercholesterolemic rabbits (Chi et al.,
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2004). This model closely mimics human atherosclerosis, which involves two distinct
pathological processes – conventional atherogenesis at early stages, and atherothrombosis at
advanced stages, which is responsible for acute manifestations of the disease (Libby, 2000). In
this model, PF-04886847 administered as an i.v. infusion during plaque rupture reduced
thrombus mass in a dose-dependent manner (Table 10). Further, PF-04886847 at 1 mg/kg
significantly prolonged both PT and aPTT, suggesting that at this dose, the compound blocked
both extrinsic and intrinsic pathways of the coagulation system. However, aPTT was prolonged
more than PT, suggesting that PF-04886847 is a more selective inhibitor of the intrinsic pathway
(i.e. plasma kallikrein). Nevertheless, since both extrinsic and intrinsic pathways of the
coagulation system have been shown to contribute to the thrombogenicity of atherosclerotic
plaque, PF-04886847 represents a promising novel anti-thrombotic compound that could be used
to prevent the life-threatening consequences of acute atherothrombosis, such as AMI and AIS
(Khrenov et al., 2002; Ananyeva et al., 2002).
Interestingly, regardless of its effect on thrombus mass, PT and aPTT, in the rabbit model
of thrombosis, PF-04886847 at 1 mg/kg had a modest effect on BT (~1.3 fold prolongation)
(Table 10). In contrast, in the rat model of LPS-induced sepsis, the same dose of PF-04886847
produced a ~1.9 fold prolongation of BT (Table 9). These differences could be attributed to the
different techniques used for measuring BT in the two models (template ear bleeding time vs. tail
tip transaction), the different time points at which BT was measured (< 0.5 vs. 6 hrs post drug
infusion) and/or species differences in pharmacokinetics of the compound resulting in variation
in the effective plasma concentration.
Of note, plasma kallikrein immunolabeling has been demonstrated in endothelial cells,
foamy macrophages, inflammatory cells and fibroblasts within the thickened tunica intima as
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well as in vascular smooth muscle cells (VSMC) of the underlying tunica media of blood vessels
affected with patchy atheromatous disease (Cerf et al., 1999). Besides, the assembly and
activation of plasma KKS on VSMC with subsequent BK production and p44/42 mitogenactivated protein kinase (MAPK) phosphorylation has been described (Fernando et al., 2005).
Douillet et al. have shown that BK-dependent MAPK pathway activation leads to VSMC fibrosis
via TGF-β1 (Douillet et al., 2000). These data suggest that plasma kallikrein-dependent BK
production might have an important role in the pathogenesis of atherosclerotic plaque formation
via modulation of TGF-β1. The rabbit model used in this study mimics both stages of
atherosclerotic disease – development of an atherosclerotic plaque and thrombus formation. In
the present study, we only evaluated the effect of PF-04886847 on the latter stage of thrombus
formation after acute plaque rupture. However, given the aforementioned evidence, it would be
interesting to examine the effect of PF-04886847 on the initial stages of atherosclerotic plaque
development as well. PF-04886847 might influence (retard or promote) the formation and/or
stability of atherosclerotic plaque through modulation of key events such as leukocyte infiltration
in the tunica media and TGF-β1-mediated VSMC migration, proliferation and extracellular
matrix turnover (Libby et al., 2002; Hansson et al., 2006; Grainger, 2004). Thus, PF-04886847
could be useful in elucidating the role of plasma kallikrein and BK in the pathogenesis of
atherosclerosis
In summary, our findings suggest that PF-04886847 is a potent and selective inhibitor of
plasma kallikrein that has excellent potential to become a novel therapeutic strategy for
suppressing kallikrein-mediated inflammatory and/or thrombotic disorders. The effects of PF04886847 on leukocyte and platelet dynamics during sepsis as well as its influence on BT are
potential areas that warrant further investigations.
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